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INFLAMMATION-RESOLVING LIPID MEDIATORS PROMOTE REVASCULARIZATION TO 
ENHANCE WOUND HEALING 
Michael J. Zhang 
May 10, 2014 
Wound healing is a highly concerted cellular process that begins with inflammation and proceeds 
to resolution to revascularize the site of injury. Although inflammation is essential to 
revascularization during wound healing, it is now recognized that resolution is an active process 
that is equally important. Other investigations have implicated a beneficial effect of resolving 
inflammation and promoting resolution in the remission of inflammatory pathologies. Recently 
investigations have yielded a novel class of ω-3 fatty acid derived lipid mediators, biosynthesized 
by leukocytes, which are capable of resolving inflammation and promoting resolution. We 
therefore hypothesized that these leukocyte-derived pro-resolving lipid mediators can promote 
revascularization to enhance wound healing. In the following studies, we provide evidence 
supporting this hypothesis: 1) that the ω-3 fatty acid derived pro-resolution lipid mediator 
Resolvin D2 enhances perfusion recovery of ischemic tissue 2) that inflammatory monocytes, 
which increase during revascularization, synthesize Resolvin D2 through the 12/15-lipoxygenase 
pathway 3) and that resolvin D2 does not stimulate angiogenesis, but stimulates arteriogenesis 
through the promotion of endothelial cell migration. These results suggest that Resolvin D2 can 
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What is Inflammation 
Historical perspective on inflammation 
 One of the defining characteristics of biological systems is the capacity to maintain 
oneself through self-repair. Unicellular organisms, such as bacteria, are capable of repairing 
damaged DNA
1
. Multicellular invertebrates such as annelids can regenerate entire body 
segments
2
. Important agronomic plants can inosculate their vasculature following graftage
3
. 
Humans can repair skin tissue after traumatic abrasions
4
. All of these reparative processes require 
tightly orchestrated molecular and cellular actions. While the amoeba is confined to autologous 
repair mechanisms
5
, multicellular organisms of greater evolutionary complexity have the luxury of 
specialized cells that concentrate on ameliorating injury.  
 A common injury that afflicts multicellular organisms, such as humans, is bacterial 
infection. The body’s reparative response to this attack is broadly termed inflammation. In the 
Smith Papyrus, a scroll written around 1650 BCE in Egypt, a hieroglyphic word used in connection 
with infected wounds contained a flaming brazier, to convey the idea of a “hot thing”
6
. Later in 
Greek medicine, infected wounds were described with the word phlegmoné, roughly translated as 
“the burning thing”. Finally the Roman, Celsus, established the precise clinical definition rubor et 
tumor cum calore et dolore, “redness and swelling with heat and pain” as the cardinal signs of 
inflammation
7
. Centuries later, Julius Cohnheim published a key manuscript describing in vivo 
evidence of these cardinal signs in frog mesentery and tongue
6







living frog under a microscope, causing irritation. This inflamed state immediately produced 
arteriolar dilation and accelerated blood flow in the entire vascular network. Minutes later, blood 
flow slowed and some white blood cells began to adhere to the venule walls. Then, slowly, the 
adhered cells began to squeeze through venule walls and occupy extravascular space. Finally, 
blood flow halted in some venules that appeared collapsed with tight aggregations of red blood 
cells. Cohnheim made the inference that plasma had escaped the venule into the tissue due to 
increased vascular permeability. He had also made the first explanation of the cardinal signs of 
inflammation: vasodilation caused rubor; increased blood flow generated calore; transudation of 
white blood cells and exudation of plasma produced tumor; and surely the frog was not spared of 
dolore. This series of observations and insights remains a foundational description of 
inflammation: the highly concerted and multi-modal sequence of blood-borne and tissue-
resident responses elicited by endogenous tissue damage or exogenous pathogenic assault.  
The fundamental role of this complex response sequence is to protect the host by limiting 
tissue damage and then facilitating tissue repair
7
. Tissue damage encompasses bacterial 
infections, but also includes other microbial pathogens, traumatic wounds, ischemic damage and 
even autoimmune attacks. These insults must be swiftly contained to prevent festering of the 
damage. Tissue-resident macrophages are capable of phagocytosing microbial pathogens and 
thus trapping them in digestive lysosomes
8
. Infiltrating neutrophils will palisade around large 
clusters of assailants to form quarantining granulomas
9
. Once the damage is contained, 
inflammation then transitions to prevent future damage and regenerate the injured tissue
7
. 
Lymphocytes are recruited to recognize, then memorize, the offending pathogens and patrol the 
host for future attacks. Macrophages complete the phagocytic cleanup of the necrotic or 
apoptotic detritus, and also digest the extracellular matrix to create virgin space for regenerating 







cells to rebuild vasculature, fibroblasts to reconstruct the collagen matrix, and the differentiation 
of stem cells to specialized parenchymal cells. The renowned pathologist Rudolf Virchow 
recognized a fifth cardinal sign of inflammation, functio laesa, disturbed function10. While this is 
certainly true during the inflammatory response, the desired endpoint of inflammation is 
complete elimination of noxious stimuli and the reestablishment of tissue function.  
This ability to self-repair is what differentiates biological from mechanical systems, as a 
result they are infinitely more adaptable and enduring. The caveat of this longevity is competition 
among biological systems (animals vs. plants vs. microbes) for scarce resources. However, one 
outcome of this struggle appears to be a permanent alliance: a presumed inflammatory reaction 
in a eukaryote resulted in the phagocytosis of a prokaryote that symbiotically specialized into 
mitochondria11. Humans are the aggregates of successive alliances between a highly specific 
social order of cells12. Inflammation is one such alliance that empowers humans to overcome 
external insults and repair internal wounds.  
 
The Inflammatory Response 
Given the remarkable capabilities of the human inflammatory response, it is the subject of 
intensive scientific investigation. Since Cohnheim’s significant observations, the organular, cellular 
and molecular timecourse of inflammation has been comprehensively documented in both 
humans and model organisms such as mus musculus. The timecourse first begins with the 
triggering of inflammation; this is precipitated by exogenous microbes or endogenous necrosis
11
. 
The onset of inflammation is then rapid, typically minutes, and then escalates over the course of 
hours. Waves of infiltrating leukocytes and perfused protein and lipid mediators from the blood 
work in concert with resident cells to cordon, then neutralize, the source of injury. This phase of 







of inflammation subside and the escalated response shifts to resolution of inflammation phase. 
Now a new group of leukocytes and mediators prevail to quench the initial inflammatory escalate 
and debride the damage site. This cleansing of damage then facilitates the final proliferation and 
remodelling phase where vascular, structural and parenchymal cells repopulate. Inflammation 
thus abates with the return of the injured tissue to functional homeostasis.  
 
Initiation of inflammation 
Exogenous pathogens can easily tilt the delicate poise of homeostasis to trigger 
inflammation through stimulation of cellular pattern recognition receptors. Viruses, bacteria, fungi 
and parasites all produce virulence factors designed to invade a host, colonize a niche and then 
reproduce progeny. The inflammatory response is able to neutralize these factors with an arsenal 
of molecular sensors. One large class of sensors is the pattern recognition receptors (PRR)
7
. These 
receptors bind to unique moieties of pathogens that are not present in the host. Toll-like 
receptors, named after the drosophila gene Toll, are a large sub-class of PRR with a common 
receptor domain mostly on leukocyte cell surfaces that recognize a wide range of bacterial and 
fungal lipoproteins, glycolipids, and unmethylated DNA sections. C-type lectin receptors are 
another large class of PRRs existing predominantly on dendritic cells and macrophages that bind 
primarily to microbial carbohydrates in a calcium dependent manner. Ligands for these receptors 
have been discovered on HIV virus, mycobacteria, candida and leishmania. Nucleotide-binding 
oligomerization domain receptors (NOD-like receptors) are cytosolic PPRs that recognize various 
constituents of the bacterial peptidoglycan layer. Retinoic acid-inducible gene 1-like receptors 
(RIG-I-like receptors) also exist in the cytoplasm and detect double-stranded RNA from viruses. All 
of these pattern recognition receptors are able to identify their microbial targets and then interact 







exogenous pathogen sensors is the immunoglobulins that circulate in the blood or anchor to 
lymphocyte cell surfaces. Through exceedingly diverse VDJ genetic recombination and somatic 
hypermutation, B and T lymphocytes produce immunoglobulins that can recognize any antigen13. 
Although they are produced initially in the later periods of inflammation, the immunoglobulins 
that bind antigen with the highest affinity are retained. They then patrol the host to sense future 
attacks by the same pathogen. Once the returning pathogen is recognized, immunoglobulins will 
attach en masse and signal immune cells or the complement system to initiate inflammation
14
. 
This latter system is also able to sense pathogens independently. While the classical pathway of 
complement is activated by immunoglobulins, a lectin and alternative pathway can also bind to 
non-host moieties like pattern recognition receptors and then stimulate inflammation. The final 
group of pathogen sensors are inadvertent and serve a primary purpose in the host body but can 
be commandeered by pathogens for their own use. One example is the staphylococcal 
enterotoxin B and its interaction with host major histocompatibility complex class II (MHC II) 
receptor
15
. MHC II receptors are normally present on antigen-presenting cells and B-lymphocytes, 
and interact with T-lymphocytes to select high affinity immunoglobulins. Enterotoxin B binds to 
the MHC II receptor directly, and stimulates a violent and non-specific inflammatory response by 
the antigen-presenting cells. This resulting torrent of inflammation presents clinically as toxic 
shock syndrome. Fortunately most sensors of exogenous pathogens are highly specific and only 
stimulate tightly controlled inflammatory responses.  
Not all signals of inflammation derive from exogenous pathogens; endogenous injuries 
must be rapidly identified as well. In the case of traumatic wounds, much of the injury is to 
endogenous tissue and vasculature. Cells in these wounds do not apoptose in an inert fashion but 
instead rupture necrotically to spew their protein and nucleic acid contents into the tissue or 
blood
7







mobility group protein 1 (HMGB1) is an abundantly expressed nucleosome protein16. When it is 
discharged from the cell during necrosis, it can directly stimulate leukocytes to generate 
inflammatory mediators. Uric acid is a ubiquitous metabolite of cellular purine recycling. When it 
is unintentionally released outside the cell, it combines with higher levels of free sodium to form 
monosodium urate microcrystals. These crystals are potent stimulators of inflammation, 
evidenced during an episode of gout. Many more highly expressed intracellular proteins are 
directly inflammatory; these include the heat shock proteins, galectins, S100 proteins, and 
mitochondrial N-formyl peptides
17
. However since cells produce an extensive collection of 
proteins, inflammatory signals from necrotic cells are still being actively catalogued. Another 
common injury occurring in tissue is hypoxia. This occurs when uncompensated coagulopathies 
cause ischemia and deprive tissues of oxygen. The master sensor Hypoxia inducible factor 1 (HIF-
1) is constitutively expressed, but also constantly prolyl hydroxylated in an oxygen-dependent 
manner that targets the active alpha subunit of HIF-1 into the proteasomal degradation 
pathway
18
. Upon hypoxia, prolyl hydroxylation is inhibited and the alpha subunit of HIF-1 is 
stabilized. It then translocates to the nucleus to stimulate the nuclear factor κB (NF-κB) family 
inflammatory transcription factors. Because tissue damage is a frequent sequelae of tissue 
hypoxia, constant turnover of HIF-1 allows cells to rapidly respond to oxygen deprivation and 
trigger repair. Overall, the consequences of internal tissue damage can be just as noxious as 
external pathogenic invasion, thus animals have evolved numerous sensors to identify a 
disturbance of homeostasis and initiate an inflammatory response.  
 
Escalation of inflammation 
Once inflammation is triggered, the reaction is escalated with the participation of multiple 







some are indiscriminate, others are highly specific. In general the rapid onset of inflammation, 
acute inflammation, proceeds in a broadly tri-phasic sequence: vascular caliber is altered to 
increase blood flow; structural changes in the vasculature allow leukocytes and secreted 
mediators to leave the circulation; extravasation of these cells and diffusion of these molecules 
into the locus of injury to contain the damage7.  
The existence of vasculature, with its circulating leukocytes and secreted mediators, 
allows the inflammatory response to target any site where they may be required
6
. When the 
vessels perfusing the area of damage are activated by sensors of inflammation, the immediate 
reaction is sometimes a vasospasm lasting mere seconds, but always followed by prolonged 
vasodilation
7
. First the arterioles expand and then the downstream capillary beds increase blood 
flow. This increased perfusion is caused by separation of endothelial cells from stimulation by 
histamine, a nitrogenous compound produced and stored in granules in mast cells and basophils, 
and vascular smooth muscle relaxation from nitric oxide, a volatile gas generated by nitric oxide 
synthase in endothelial cells and leukocytes. Along with vasodilation there is an increase in 
vascular permeability from the activation of endothelial cells. Secreted mediators such as 
histamine, bradykinin, leukotrienes, and neuropeptide substance P cause an immediate transient 
contraction of endothelial cells, thus opening their tight junctions and allowing blood contents to 
enter the extracellular space
7
. Direct physical injury to endothelial cells will result in cell necrosis 
and detachment, also forming more vascular leakage sites. This combination of dilation and 
permeability results in fluid loss to the extracellular space and a retardation of blood flow
7
. 
Erythrocytes accumulate as a result, increasing the local viscosity of blood in already dilated 
vessels, and producing a local rubor
7
. More importantly, leukocytes, platelets and secreted 
mediators all accumulate as well.  







neutrophil14. These cells arise from hematopoetic stem cells in the bone marrow and bear 
unusually lobular and segmented nuclei. As stasis develops in dilated and permeablized 
vasculature, neutrophils begin to migrate away from the center of blood vessels towards the 
margins near the endothelial surface. Specific adhesion molecules, such as selectins and integrins, 
produced by both neutrophils and activated endothelial cells allow neutrophils to slow, roll, and 
then arrest on the endothelial surface. Neutrophils produce L-selectin and endothelial cells 
produce E-selectin and P-selectin to facilitate the slowing and rolling process
19
. These selectins 
are normally stored in intracellular granules, but redistribute to the cell surface following 
histamine and other secreted mediators to allow binding of both cell types to various sialylated 
oligosaccharide-linked mucin-like glycoprotein backbones. Subsequently, neutrophils produce 
integrin α4β1 and integrin αLβ2, while endothelial cells correspondingly produce vascular cell 
adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) to consolidate the 
neutrophil-endothelium adhesion
19
. Once adhered, the neutrophil rearranges its cytoskeleton and 
spreads out on the endothelium towards secreted mediator gradients that direct it past the 
endothelial layer, through the basement membrane and into the damaged tissue.  
Once infiltrated into the inflamed site, neutrophils begin the process of wound 
debridement. They surround loci of invading pathogens or necrotic tissue by palisading and begin 
the complex process of phagocytosis
7
. This involves three sequential stages: recognition and 
attachment to tissue injury agents; engulfment of these agents into a phagolysosome; and finally 
the digestion or degradation of ingested contents. The three primary recognition receptors 
involved in the process are mannose, scavenger, and opsonin receptors. Mannose receptors bind 
to glycoproteins and glycolipids found on microbial cell walls but not mammalian membranes
20
. 
Scavenger receptors were originally characterized as gatherers of oxidized or acetylated low-







scavenger receptors have now been found to also bind a variety of pathogenic microbes21. Fc 
receptors are the largest group of opsonin receptors22. They are members of the immunoglobulin 
superfamily and recognize various Fc regions of different antibody classes. After circulating 
antibodies bind to pathogenic targets, leukocytes attach via Fc receptors, or mannose and 
scavenger receptors independently, and begin the engulfment process
7
. Pseudopodic extensions 
of leukocyte cytoplasm, formed by small guanine triphosphate hydrolases (GTPases) stimulated 
actin filament polymerization, surround the microbe and pinch off to form an intracellular 
phagocytic vesicle (phagosome). This phagosome then fuses with a digestion enzyme-containing 
lysosome and becomes a phagolysosome. Next, the multiprotein NADPH oxidase complex 
translocates to the phagolysosomal membrane and releases reactive oxygen species within the 
isolated phagolysosome. This is not sufficient to neutralize pathogens completely however. 
Myeloperoxidase (MPO) contained within neutrophil granules then combine with reactive oxygen 
species, in combination with intracellular chloride, to form hypochlorite. This is the most potent 
antimicrobial agent due its non-specific covalent halogenation and oxidation of microbial cell 
constituents. The destroyed microbes are either fully digested by the fused lysosomal enzymes or 
released into the interstitium via the plasma membrane. Dead host cells can be digested in this 
same process, however their recognition is, by necessity, different from pathogens. These dead 
cells are identified by phagocytes through a set of colloquially termed find me and eat me 
signals
23
. Find me signals include fractalkine, lysophosphatidylcholines, sphingosine-1-phosphate 
and P2Y-binding nucleotides. Eat me signals include phosphatidylserine, oxidized LDL, calreticulin 
and altered cell surface glycoproteins. Cells that produce these signals can be damaged 
parenchymal cells and vascular cells, but also includes recently infiltrated neutrophils that have 
already phagocytosed microbes or debris and are apoptosing themselves. Finally, concomitant 







that further propagate inflammation by recruiting more leukocytes. 
The secreted mediators of inflammation are a hugely diverse group of molecules that are 
produced in a highly coordinated manner that largely determines the onset, magnitude and 
duration of the reaction. Inflammation mediators are produced by cells or assembled from plasma 
proteins
7
. Cell-derived mediators are either stockpiled a priori in intracellular granules for rapid 
secretion (e.g., histamine in mast cell granules) or generated specifically in response to 
inflammatory stimuli (e.g., prostaglandins, cytokines). The primary producers of these mediators 
during inflammation are platelets, neutrophils, monocytes, macrophages, mast cells, endothelial 
cells, smooth muscle cells and fibroblasts. Plasma-derived mediators, such as the complement 
system and coagulation system, are released from the liver as inactive zymogens circulating in the 
blood that must be activated through proteolytic cleavage during inflammation. Both cell and 
plasma derived mediators are only activated by sensors of inflammation to ensure both a highly 
specific and timely response to tissue injury. Once activated, mediators cascade by stimulating the 
release of other mediators to amplify the original sensor response. These mediators affect 
assortment of cellular targets; they can affect several different types of cells simultaneously or 
effect different responses in different cells. And finally, once activated, most mediators are then 
rapidly inactivated through enzymatic degradation (arachidonic acid metabolites), molecular 
scavenging (reactive oxygen species) or molecular inhibition (antithrombin) to limit the 
inflammatory response to only what is sufficient to address the injury.  
Histamine and serotonin are the two major vasoactive amines that act as secreted 
mediators of inflammation. Both molecules are preformed and stored in intracellular granules for 
rapid secretion, typically on the precipice of inflammation. Histamine is produced by both 
immune cells and cells of the digestive system, but during inflammation, their primary reservoir is 
the mast cell
24







C3a and C5a anaphylatoxins of the complement system, neuropeptides, and cytokines and 
chemokines, can all stimulate mast cell degranulation of histamine. Once released, histamine 
binds to H1 G protein-coupled receptors on endothelial cells to increase interendothelial gaps 
and thus more vascular permeability. Meanwhile, serotonin stimulates this same effect from 
release by platelet degranulation after contact with collagen, thrombin, adenosine diphosphate or 
certain antibody-antigen complexes
25
. In fact, serotonin can mediate the transformation of the 
desert locust, Schistocerca, from a benign solitary state to the gregarious phase responsible for 
sky-darkening and crop-destroying swarms; perhaps there are some fractal analogies in 
serotonin-signaled processes
26
. While these two amines are often the first initiators of 
vasodilation due to their preformed nature, many more inflammatory vasodilators are produced. 
Nitric oxide (NO) is another nitrogen-containing vasoactive mediator. NO is a volatile and 
highly soluble gas produced by three separate enzymes; endothelial nitric oxide synthase (eNOS) 
in endothelial cells; inducible nitric oxide synthase (iNOS) in leukocytes; and neuronal nitric oxide 
synthase (nNOS)
27
. NO has diverse cellular roles. During bacterial infections, NO in leukocytes 
serves a microbicidal role by interfering with metal centers and thiols necessary for respiration 
and DNA replication. Extracellularly, due to the mere-seconds half-life of NO, it only acts in a 
paracrine manner on neighboring cells and principally through the stimulation of cyclic guanosine 
monophosphate (cGMP). cGMP then initiates a series of intracellular pathways that stimulate 
vascular smooth muscle relaxation, platelet aggregation and adhesion reduction, mast cell 
stabilization and leukocyte infiltration attenuation. Thus NO not only stimulates inflammation, 
through smooth muscle vasodilation, but also inhibits inflammation, through blood cell inhibition.  
Reactive oxygen species (ROS) are another group of volatile secreted mediators of 
inflammation. They include the superoxide anion, hydrogen peroxide and hydroxyl radicals
28
. 







generated by the NADPH oxidase system in leukocytes after exposure to microbes, antibody 
complexes or other secreted inflammatory mediators. The primary objective of ROS generation is 
to neutralize phagocytosed microbes, but due to their highly diffusive nature, they are also 
capable of damaging other cells and molecules. Damage to endothelial cells will further increase 
vascular permeability; inactivation of α1-antitrypsin can cause inadvertent extracellular matrix 
destruction through unopposed protease activity. However, not all highly diffusive inflammatory 
mediators are directly cytotoxic. 
Lipid derived inflammatory mediators are also able to readily cross cellular membranes to 
act as soluble mediators of inflammation. The largest and most diverse group is the 
polyunsaturated fatty acids (PUFA) such as linoleic acid, arachidonic acid, eicosapentaenoic acid, 
and docosahexaenoic acid
14
. These PUFAs are normally sequestered in esterified form within 
plasma membrane phospholipids. During inflammation, cellular influx of calcium or other 
mediators stimulate phospholipase (primarily A2) to liberate the PUFAs from the membrane to be 
converted by cyclooxygenases into prostaglandins and lipoxygenases into leukotrienes. 
Cyclooxygenase 2 is induced during inflammation and biosynthesizes prostaglandin lipid 
mediators
14
. Various lipoxygenase enzymes operate in succession to produce an even larger class 
of mediators that include leukotrienes and lipoxins
29
. Despite their varying biosynthetic pathways, 
all lipid mediators interact with G protein-coupled receptors, as agonists or antagonists (or 
inverse agonists) to direct or influence all phases of inflammation. Because they were discovered 
first, prostaglandins have been the most extensively characterized. They are biosynthesized by 
many cell types, including mast cells, neutrophils, macrophages and endothelial cells. The most 
abundant products generated during inflammation are prostaglandin E2 (PGE2), PGD2, PGI2 and 
thromboxane A2 (TxA2)
14
. Mast cells generate abundant PGD2 to stimulate vasodilation, increase 







vasodilator and it inhibits platelet aggregation. Conversely, TxA2 is synthesized by platelets, and 
stimulates platelet aggregation and promotes vasoconstriction. PGE2 is the most widely 
distributed and most abundantly generated cyclooxygenase product, however the diverse actions 
of PGE2 are still under intense investigation
30
. Like its isomer PGD2, PGE2 can stimulate mast cell 
degranulation to cause vasodilation or it can stimulate vasodilation directly through four EP 
receptors. PGE2 can enhance neutrophil infiltration and promotes activation, maturation and 
migration of dendritic cells. However, paradoxically, PGE2 can limit the phagocytic capability of 
alveolar macrophages. It can suppress some of the cytolytic capabilities of natural killer cells. PGE2 
can also indirectly propagate inflammatory pain and systemic fever. Finally, PGE2 can stimulate the 
anti-inflammatory cytokine, IL-10 as well. In short, PGE2 has different effects on different cells, and 
more recently appreciated, has different effects at different time points during inflammation. The 
production, targeting and effects of PGE2 are thus highly context dependent. Because eicosanoids 
readily traverse cell membranes, have minute but highly specific steric differences, and act mostly 
in a local paracrine mode, there are major technical limitations in monitoring their biosynthesis 
and movement spatially and in real-time
31
. However, as previously alluded, one major conceptual 
realization recently has been temporal importance of their biosynthesis
32
. TxA2 and PGI2 are 
produced primarily during the initiating phases of inflammation. Then eicosanoid production 
shifts to another class, leukotrienes (described later) to stimulate leukocyte infiltration. The later 
phases of inflammation, pathogenic and cellular debris cleanup, and parenchymal 
reestablishment, are influenced by another set of eicosanoids, lipoxins and resolvins. Therefore 
the context dependent paradoxical actions of PGE2 could be simply the result of temporal 
synthesis differences. As detection technologies improve for eicosanoids, this temporal factor will 
become better characterized and understood.  







as soluble mediators of inflammation as well33. There are many different isoforms of 
lipoxygenases, resulting in a huge variety of biosynthetic products. The most extensively 
characterized are the 5-lipoxygenase products leukotriene B4 (LTB4) and cysteine residue-
containing LTC4, LTD4 and LTE4. The cysteinyl leukotrienes are powerful vasoconstrictors that 
cause bronchospasms, but they also increase vascular permeability and stimulate endothelial cells 
and many different leukocytes. LTB4 has similar actions and is also an extremely potent neutrophil 
chemoattractant. It is generated most abundantly after the initial edema phase of inflammation 
during which neutrophil infiltration is at its peak. Many different types of leukocytes can produce 
LTB4, including the neutrophil itself. Furthermore, LTB4 production is not always confined to a 
single cell. In vitro studies of coincubated leukocytes have demonstrated that biosynthetic 
enzymes of the LTB4 pathway in different cells can operate synergistically to produce additional 
LTB4 product. Thus in addition to specific temporal generation, eicosanoids are capable of 
transcellular synthesis. Undoubtedly, much remains to be elucidated in eicosanoid biology.  
The final group of cell-derived inflammatory mediators, cytokines and chemokines, is the 
most diverse, most investigated, most targeted pharmaceutically, and yet remains incompletely 
understood. The majority of cytokines are involved in inflammation primarily through their 
utilization by the adaptive immune system are thus not directly involved in the acute 
inflammatory response
7
. Tumor necrosis factor alpha (TNFa) and interleukin-1 (IL-1), however, are 
primary mediators of inflammation
7
. In general, TNFa and IL-1 are produced by activated 
monocytes and macrophages in response to stimulation by bacterial toxins, immune complexes 
and physical injury. Unlike NO and eicosanoids, the effects of TNFa and IL-1 are both local and 
systemic. TNFa can affect the hypothalamus, and induce fever and suppress appetite. It can also 
stimulate neutrophil infiltration and macrophage phagocytosis. Along with IL-1, it can activate the 







thrombogenicity of the endothelium, and it can increase the production of other cytokines, 
chemokines, growth factors, eicosanoids, nitric oxide and matrix remodeling enzymes. Due to 
their far-reaching inflammatory effects, TNFa and IL-1 are both targets of several relatively novel 
anti-inflammatory drugs. Aside from these two major cytokines, Interleukin-6 is also the subject of 
intensive investigation. Again it is primarily secreted by macrophages and is involved in the 
initiation of fever by crossing the blood brain barrier and stimulating the hypothalamus. 
Interleukin-17 is a relatively novel cytokine
34
. Unlike many other cytokines, it is produced by T-
helper lymphocytes, and it stimulates the production of numerous other cytokines and 
chemokines by other leukocytes. Uniquely, it is often secreted during autoimmune diseases, 
leading investigators to propose IL-17 as a therapeutic target. The list of cytokines implicated in 
inflammation is large and expanding; intense interest in their role as therapeutic targets only 
reinforces their critical importance in inflammation.  
Chemokines are a specialized subgroup of cytokines. They are small proteins, eight to ten 
kilodalton in size, that behave primarily as chemoattractants for different types of leukocytes
7
. To 
date, more than forty chemokines, overlapping over twenty corresponding receptors, have been 
described. They are classified according to the arrangement of their one or two pairs of 
crosslinked cystine residues. The C-X-C chemokines are primarily neutrophil chemoattractants; 
CXCL8 (formerly known as interleukin-8) is a prototypical member
35
. It is secreted by activated 
endothelial cells and macrophages and binds the CXCR1 and CXCR2 G protein-coupled receptors 
on neutrophils to stimulate migration and phagocytosis. The C-C chemokines are more diverse 
are attract a range of leukocytes except neutrophils. Monocyte chemoattractant protein 1 (aka 
CCL2) is an essential recruiter of blood monocytes to sites of inflammation
36
. Eotaxin (aka CCL11) 
is unique in its ability to attract eosinophils, a rare blood-borne granulocyte important in airway 
inflammation and parasitic infections
37







(regulated and normal T-cell expressed and secreted, CCL5) and macrophage inflammatory 
protein-1α (CCL3)38. The C chemokines contain only one pair of cysteine crosslinks. Only two 
family members have been discovered and both primarily attract lymphocytes. The CX3C 
chemokine family contains only one member, fractalkine (CX3CL1)
39
. It is an unusually large 
protein at 42 kilodaltons and exists as both cell surface-bound or soluble forms. CX3CL1 is 
produced by endothelial and smooth muscle cells during inflammation to stimulate migration, 
adhesion and proliferation of monocytes, natural killer cells and T-lymphocytes. Overall, 
chemokines can be secreted constitutively in tissues under homeostatic conditions simply to 
organize different cells to different organ systems; however they are also strongly induced during 
inflammation and participate in eliciting leukocytes to sites of injury.  
A majority of secreted inflammatory mediators is cell-derived, but the complement 
system and the coagulation system are two very specific systems of plasma-derived mediators 
that play an integral role in the escalation of inflammation
14
. Both systems are comprised of 
proteins expressed primarily in the liver and then circulated through the blood. The complement 
system consists of approximately twenty proteins numbered C1 through C9. While its primary 
functions are in the innate and adaptive immune response to microbial pathogens, its collateral 
effects during inflammation are profound. Three separate pathways exist: the classic pathway is 
triggered by binding of C1 to antibody-antigen complexes; the alternative pathway is activated by 
microbial surface antigens; the lectin pathway is stimulated by microbial surface carbohydrates
11
. 
All three pathways converge on the formation of enzyme C3 convertase which cleaves specific 
complement system proteins to form C3a, C3b and C5a. C3a exerts a major effect on 
inflammation through the direct stimulation of histamine release from mast cells. C3b can affix to 
microbial cell walls and act as opsonins to attract phagocytosing neutrophils and macrophages. 







the complement system can produce certain proteins that contribute to the orchestration of 
inflammation. Separately, the coagulation system is also closely intertwined with inflammation40. 
The vasculature is normally a closed system, but physical rupture of epithelial surfaces such as the 
skin is both the primary opportunity for pathogenic invasion and most common active site for 
coagulation. The first phase of coagulation is platelet activation to form a platelet plug to stem 
hemorrhaging. Platelets degranulate serotonin, platelet activating factor and CXCL4, and generate 
ADP and TxB2, all secreted mediators described previously. Additionally, active thrombin, 
generated during the extrinsic clotting pathway, can enhance inflammation through protease-
activated receptors (PARs) expressed on platelets, endothelial and smooth muscle cells to increase 
leukocyte adhesion receptor expression, cytokine and chemokine production, and NO and PAF 
generation. Additionally, the fragment fibrin byproducts of plasmin-catalyzed fibrinolysis can also 
enhance inflammation through interactions with C3 in the complement system. In summary, the 
complement and coagulation systems are major plasma-derived biological processes with many 
common mediators of inflammation.  
 
Resolution of inflammation 
Once the original offending agents are contained, inflammation must resolve in order to 
allow tissue regeneration and restoration of homeostatic normality
41
. Historically, many well 
characterized mediators of inflammation were found to appear transiently; NO has a half-life of 
mere seconds, TxA2 is rapidly degraded as well, even the neutrophil is only present at 
inflammatory sites for one to two days before undergoing apoptosis
7
. Therefore it appeared self-
evident that inflammation was a self-limiting process wherein mediators passively subsided once 
the source of injury was neutralized. However, the discovery of inflammatory mediators that only 







field to realign definitions and update terminology42. Two major classes of inflammation 
suppressing drug classes are the cyclooxygenase-inhibiting nonsteroidal anti-inflammatory drugs 
(NSAIDs) and the immunosuppressing corticosteroids
40
. By inhibiting cyclooxygenase, NSAIDs 
reduce the production of all eicosanoids, and by disrupting leukocyte maturation, proliferation 
and activation, corticosteroids diminish the synthesis of cytokines and chemokines. Since both 
classes of drugs actively inhibit the process of inflammation, a negative event, they are 
appropriately termed anti-inflammatory. However, the production of IL-10 and LxA4 are positive 
events
43
. Therefore while they also oppose the propagation of inflammation, they are not just 
anti-inflammatory, but also pro-resolving, or promote resolution of inflammation. Within this new 
framework, the phagocytosis of microbes and necrotic and apoptotic cells, the egress of 
macrophages and dendritic cells from inflammatory sites to lymph nodes and the spleen, and the 
production of late-phase secreted mediators, are all pro-resolving actions occurring during the 
resolution phase of inflammation. Excessive production of inflammatory mediators, like reactive 
oxygen species, fever-inducing TNFα, and excessive hemostatic plugs can exacerbate the original 
tissue injury, negating any positive effect of inflammation
43
. Thus resolution of inflammation must 
be timely implemented to tilt the inflammatory poise toward eventual restoration of tissue 
homeostasis. 
A primary event in resolution is the secondary engulfment of apoptotic neutrophils that 
have already phagocytosed wound contents by monocyte-derived cells
44
. Due to their relative 
abundance circulating in blood, and their targeting by chemokines and adhesion molecules, 
neutrophils are the initial infiltrating cell type to inflammatory sites and thus the first to begin 
phagocytosing. Monocytes must be recruited from the splenic reservoir or differentiated from the 
bone marrow, thus they arrive approximately twenty-four hours later
45
. Although they also 







dendritic cells that not only phagocytose but then egress to physically remove inflammatory 
debris. This collective function is termed efferocytosis46. What differentiates this secondary 
phagocytic activity from primary neutrophil phagocytosis of invading pathogens or dead cells is 
the lack of concurrent pro-inflammatory mediator release. When monocyte-derived cells ingest 
apoptotic neutrophil, they do not secrete cytokines or chemokines that recruit more leukocytes, 
such as TNFα or IL-8. They are instead non-phlogistic; they do not stimulate inflammation 
further
47
. As a result, monocyte-derived macrophages and dendritic cells, which appear later than 
neutrophils, are the ultimate cleansers of the damage site, blanching it of any cells or mediators 
that can elicit further inflammation. After phagocytic cleanup, they can migrate via blood or 
lymphatics to lymph nodes or the spleen for antigen presentation or complete degradation.  
Corresponding to inflammation, resolution is also mediated by secreted mediators. Of 
these, IL-10 is the most prominent example of a resolution phase cytokine
48
. It is expressed 
primarily by monocytes and macrophages, and it elicits a host of effects that generally quell the 
propagation of inflammation. It interferes with the pluripotent inflammatory transcription factor 
nuclear factor kappa B (NF-κB) transcription pathway in leukocytes, thus severely diminishing the 
production of inflammatory mediators such as IFN-γ, TNFα, IL-2, and GM-CS. IL-10 can also 
modulate the expression of cyclooxygenase 2, and thereby reduce synthesis of inflammatory 
prostaglandins and leukotrienes. Another important pro-resolving mediator is transforming 
growth factor β (TGFβ)
49
. Macrophage secreted TGFβ can inhibit inflammatory signaling of Toll-
like receptors, which are important pattern recognition sensors of microbes. TGFβ can reduce the 
production of ROS by neutrophils. TGFβ can inhibit proliferation of IL-2 dependent T-cells and 
activation of cytotoxic T-cells. Finally, TGFβ can stimulate extracellular matrix deposition by 
mesenchymal cells; this is critical for repairing the pathogen, trauma and inflammation-damaged 







but the reason for this heterogeneity is still not well understood. Another pro-resolving mediator 
is the relatively novel Annexin A150. It can promote neutrophil apoptosis during inflammation and 
also stimulate their subsequent phagocytosis by macrophages. Neutrophils generate many 
secreted inflammatory mediators, such as ROS and hypochlorite, which have high collateral 
damage potential. Thus encouraging their quiet resignation also promotes the resolution of 
inflammation. 
Lipid mediators are also produced during the resolution of inflammation. Just as TxB2 and 
PGI2 have counteracting vasoconstrictive and vasodilatory actions, several pro-resolving lipid 
mediators can oppose the inflammatory effects of prostaglandins and leukotrienes. Lipoxin A4 
(LXA4) is a relatively novel but well characterized example of a pro-resolving lipid mediator
29
. It is 
biosynthesized from arachidonic acid in three main pathways: by 5-lipoxygenase and 12-
lipoxygenase in leukocytes; by 15-lipoxygenase in parenchymal cells first then transcellularly 
though leukocyte 5-lipoxygenase; or from direct transformation by 5-lipoxygenase of membrane 
inositol-containing lipids stores of 5-HETE. The major actions of lipoxins are to decrease vascular 
permeability, decrease neutrophil-endothelium interactions and reduce neutrophil infiltration. 
LXA4 can also stimulate macrophage phagocytosis of microbes and apoptotic neutrophils. 
Overall, the major actions of LXA4 oppose the preceding actions of LTB4 and cysteinyl 
leukotrienes. Furthermore, since LXA4 sometimes share the same intermediate LTA4 substrate as 
LTB4, the diversion of AA products into LXA4 actually directly reduces LTB4 biosynthesis
51
. 
Another example of a resolution-phase lipid mediator is the resolvins
52
. These are also 
lipoxygenase products, but they are bioynthesized from eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) precursors rather than arachidonic acid. While they have many 
actions similar to LXA4, they do not always bind the same G protein-coupled receptors, and new 







described53. It is an EPA-lipoxygenase product that directly inhibits LTB4-stimulated neutrophil 
transmigration in vitro. RvE1 can inhibit both ADP-stimulated activation of P2Y12 and the effects 
of TxB2, to prevent platelet aggregation. In addition, RvE1 can directly block the transient 
receptor potential (TRP) family of nociceptors on skin keratinocytes and peripheral sensory 
neurons to mute inflammatory pain
54
. The D-series resolvins are derived from DHA and share 
many effects with the E-series resolvins. One novel effect of resolvin D2 (RvD2), is the increase of 
antibiotic efficacy during infection without direct antimicrobial actions
55
. However, much remains 
left to be elucidated in pro-resolving lipid mediator biology, but interest in their unique resolution 
phase actions is intensifying and their importance in ushering a timely conclusion to inflammation 
is firmly established.  
 
Proliferation and remodeling after resolution 
The inflammatory response concludes with the proliferation and remodeling phase. Two 
broad processes occur during this phase that must be clearly separated: regeneration and repair
7
. 
Regeneration describes the proliferation of de novo cells and tissues that replace damaged 
structures and restore original functionality. Some amphibians are able to regenerate entire 
amputated limbs, but in mammals, regeneration is usually limited to small sections of liver or the 
bone marrow. More often, the process of repair concludes inflammation. What differentiates 
repair from regeneration is the formation of scar tissue rather than restoration of original 
function. Often the extent of tissue damage to the ECM and parenchymal cells, either from the 
original insult or from the resulting inflammation, is too extensive for the proliferation and 
remodeling phase to regenerate the affected tissue completely. Usually near the conclusion of the 
resolution phase of inflammation, the original pathogenic invaders and deceased host cells have 







cells can proceed. The main mediators of this phase are macrophages, fibroblasts, vascular cells, 
progenitor cells, and the milieu of secreted mediators they produce7. Macrophages are pivotal in 
the initiation of the regenerative phase. While they phagocytose microbial and cellular debris, 
they are also secrete chemokines and growth factors to promote angiogenesis and extra cellular 
matrix remodeling
56
. In particular, the release of TGFβ, platelet derived growth factor (PDGF), and 
fibroblast growth factor (FGF) signals the migration and then proliferation of fibroblasts at the 
wound site. Fibroblasts are a major type of mesenchymal cell with a branched plasma membrane 
and numerous rough endoplasmic reticulum
57
. They synthesize collagens, glycosaminoglycans, 
reticular and elastic fibers, glycoproteins found in the extracellular matrix. Initially, between 24 to 
72 h of the regenerative phase, a provisional matrix of coagulation system-derived fibrin, plasma 
fibronectin and type III collagen is established by proliferating fibroblasts and endothelial cells. 
This temporary matrix of proteins, granulation tissue, contains leaky new blood vessels that allow 
abundant passage of plasma growth factors into the extravascular space, and gradually 
reconstitutes the debrided tissue damage site. Slowly and under stimulation primarily by TGFβ, 
this granulation tissue is replaced with scar tissue through connective tissue remodeling by matrix 
metalloproteinases. Fibroblasts and macrophages produce these digestive enzymes, which 
degrade the damaged and provisional ECM while the new collagen I matrix is deposited by 
fibroblasts.  
In addition to ECM repopulation, the original parenchymal cells of the damaged tissue 
also begin to reappear through the proliferation and differentiation of various progenitor cells
58
. 
These cells can be hematopoetic stem cells, mesenchymal stem cells, or a range of tissue-specific 
progenitor cells. This is a relatively novel field in biology and the full lineage characterization of 
the various cell types is incomplete. Some features of these cells have become well accepted 







cytoplasmic organelles; they have a much greater capacity for self-renewal than somatic cells; 
some of their regenerative effects are not autologous but through paracrine effects on existing 
tissue cells; and they are highly plastic, with the ability to differentiate into a variety of 
parenchymal cell types or de-differentiate into a more pluripotent embryonic state. Often the 
regeneration of damage tissue is incomplete as accumulation of new collagen displaces 
leukocytes and leaky vasculature, and converts the area into a pale, avascular scar that does not 
retain the original tissue function. This is frequently the outcome of deep cutaneous wounds
7
. 
However, other tissues such as the liver are able to regenerate with restored function. Of course, 
there are many anatomical and cellular differences between the skin and the liver, but this 
disparity in regenerative capability remains one of the most compelling questions in biology. New 
and incoming insights from stem cell research have the potential to address this question.  
 
Wound Healing 
Wound healing is a dynamic process involving multi-modal interactions of resident and 
infiltrating cells, secreted mediators and extracellular matrix molecules tasked with the immediate 
goal of maintaining tissue integrity and eventually returning to homeostasis
59
. As such, it shares 
many processes with the inflammatory response, including the recognition of tissue damage, 
infiltration of leukocytes to remove debris, and the establishment of granulation tissue. However 
wound healing also involves other reparative and regenerative processes. In cutaneous wounds, 
wound contraction and recovery of tensile strength are instrumental in healing. Contraction of a 
surface wound decreases the gap between dermal edges and thus reduces wound surface area. A 
network of myofibroblasts, bearing many similarities to smooth muscle cells, form at the wound 
edge and produce large quantities of type I collagen, tenascin-C, osteonectin and fibronectin that 







FGF60. After the initial week of ECM deposition, the tensile strength of the contracted wound is 
merely 10% of undamaged skin7. Months later, as collagen fibers are increased in size and 
crosslinked together; tensile strength is restored to about 70-80% of the original skin. The 
ultimate recovery of cutaneous wounds is dependent on systemic and local host factors. Nutrition 
derangements, either protein or vitamin deficiency, or nutrient overload in diabetes and obesity, 
can alter significantly the timecourse or magnitude of wound healing. Compromises in circulatory 
status, such as those caused by atherosclerosis or varicose veins, can also impair wound healing. 
Locally, pathogens present the largest obstacle to proper healing, but mechanical interference at 
the wound site, foreign material, and wound size and location, are factors that can interfere with 
the orderly and timely healing of wounds. 
 
Revascularization  
Another component of wound healing is the restoration blood perfusion through 
vasculogenesis, angiogenesis and arteriogenesis
61
. Vasculogenesis is the de novo formation of 
blood vessels from incompletely differentiated but endothelial-committed progenitor cells where 
no prior vasculature existed. Angiogenesis is the sprouting of new capillaries from existing 
capillary networks by branching or recruited progenitor cells. And arteriogenesis is the diameter 
expansion of existing arteriolar connections into true collateral arteries. Vasculogenesis occurs 
predominantly during the embryonic and fetal period
62
. During gastrulation, ectodermal cells are 
recruited to the primitive streak and undergo an epithelial to mesenchymal transition. These cells 
then migrate between the visceral endoderm and epiblast, and form mesoderm through bone 
morphogenic protein 4 (BMP4) and fibroblast growth factor 2 (FGF2) stimulation. The visceral 
endoderm then secretes the growth factors indian hedgehog (IHH) and FGF2 that target the 







receptor 2 (VEGFR2) and respond to visceral endoderm VEGF to coalesce and form blood islands 
that fuse to mature into a primitive network of capillaries or vascular plexi. Once these nascent 
vascular complexes form, they are remodeled by a delicate balance of cell-cell and cell-matrix 
signals and interactions to establish a mature circulatory network
63
. Important growth factors 
during this process include VEGF and FGF2, but also retinoic acid and TGFβ, and fibronectin 
binding alpha V beta 1 (aVβ1) and alpha V beta 3 (aVβ3) integrins. Additionally, smooth muscle 
cells and pericytes are recruited to wrap the outer blood vessel walls and add contractile function. 
Eventually as the fetus grows, vasculogenesis is supplemented with the angiogenic sprouting of 
existing circulatory networks.  
Once again, VEGF (and to a lesser degree FGF2) secreted by mesenchymal and stromal 
cells remains the primary driver of angiogenesis. VEGFR2 is again the principal receptor for 
VEGF
64
. Through this signaling pair, endothelial progenitor cells are recruited from the bone 
marrow and induced to proliferate, differentiate and chemotaxi into new capillary sprouts. The 
actual process of capillary networking is still under investigation; however, a group of Notch 
ligands (Jagged 1 and 2, Delta-like 1, 3 and 4) and receptors (Notch 1-4)have been found to be 
critical mediators
65
. During the sprouting process, the leading angiogenic progenitor cell, referred 
to as a tip cell, proliferates and migrates under VEGF stimulation. They also produce delta-like 
ligand 4, which interacts with Notch 1 and 4 on the stalk cells that remain tethered to the existing 
capillary. Ligand triggering of stalk cell Notch receptors leads to receptor downregulation and 
nuclear translocation where genes that dampen VEGF responsiveness are activated. Thus through 
a signaling loop, tip cells sprout forward while leaving a tube of stalk cells that form a new vessel. 
Once formed, new vessels remain fragile until they are stabilized by the recruitment of pericytes 
and smooth muscle cells and the deposition of ECM proteins. Angiopoietins, PDGF, and TGFβ are 
the principal mediators of stabilization
66







smooth muscle cells. TGFβ enhances the deposition of ECM molecules and expression of their 
cellular receptors. The formation of a robust ECM is critical in modulating angiogenesis and 
protecting the integrity of the new vessels. Many other mediators, and hypoxic stimulus, have 
been found to enhance angiogenesis. αVβ3 integrin is stimulated by hypoxia, potentiates 
metalloproteinase activity, and interacts with fibronectin and vitronectin to assist cell spreading 
and migration
67
. Metalloproteinases and plasminogen activators allow endothelial cells to 
remodel the ECM and invade new angiogenic space
68
. Cytokines and chemokines, such as IL-6, IL-
8, CCL2, and CXCL12, can induce angiogenesis as well
69
. The list of molecules that stimulate 
angiogenesis is constantly expanding. Some are only expressed during the fetal period; others are 
only induced in tumor environments. Some molecules directly enhance angiogenesis through 
cell-matrix interactions, others only stimulate indirectly through increases in VEGF
70
. Regardless of 
stimuli, angiogenesis is a complex cellular process that is integral to wound healing.  
 Internal tissue wounds are often the result of ischemia, a restriction in blood supply, 
rather than trauma or infection. In cases of large artery occlusion, the process of angiogenesis, 
which develops over the course of days, is insufficient to rescue ischemic tissue or organs
71
. Early 
clinical trials testing the efficacy of VEGF stimulated angiogenesis in coronary heart disease 
patients was largely unsuccessful
72
. Instead, it is collateral arterioles, rather than capillaries, that 
must expand in size to compensate for the decreased blood flow. This expansion is not just 
vasodilation. The development of collateral arterioles into collateral arteries involves proliferation 
of endothelial and smooth muscle cells, hence the name arteriogenesis
73
. Because the occlusion is 
not in the collateral arteriole itself, ischemia, and therefore hypoxia, is not the primary driving 
force of arteriogenesis. Instead there is an increase in blood fluid shear stress as the collateral 
arterioles now more directly connect high-pressure vessels with low-pressure capillaries. This 







monocytes74. The resulting expanded collaterals possess numerous dividing endothelial and 
smooth muscle cells, forming a cell-rich intima. They also adopt a highly characteristic tortuosity 
as the vessel grows in both width and length. Unfortunately, even the normal arteriogenic process 
occurs over the course of days, which is insufficient to rescue such severe cases of ischemia as 
myocardial infarction or stroke where irreversible damage occurs within minutes to hours. 
Moreover, arteriogenesis is a self-limiting process
75
. When the collateral arteriole expands, the 
amount of fluid sheer stress stimulus decreases and tapers the vessel’s further expansion. Under 
normal physiological conditions, arteriogenic restoration of perfusion is therefore asymptotic, but 
given external stimuli, such as more fluid shear stress or other soluble mediator, arteriogenic 
enlargement can be enhanced. Thus, while surgical and endovascular revascularization has been 
brilliantly effective in redressing ischemia and rescuing lives, the enhancement of biological 
revascularization, arteriogenesis and angiogenesis, can further improve wound healing outcomes.  
  
Monocytes and Macrophages 
Monocytes and macrophages play an important role in the revascularization process by 
regulate both inflammation and wound healing. These cells appear early during embryogenesis
76
. 
Primitive macrophages are in the yolk sac and were first identified by Ilya Mechnikov who 
described the process of phagocytosis by a large (macro) eater (phage) cell in starfish larvae
77
. 
Subsequent work has led to the identification of the origin and fate of these primitive 
macrophages
76
. In particular, it has been shown that as development progresses and 
hematopoiesis begins in the fetal liver, hematopoietic stem cells produce a common myeloid 
progenitor cell, which in turn form monoblasts that eventually mature into monocytes. These 
monocytes are then distributed throughout the fetus in several tissues and differentiate into 







therefore have inconsistent names: histiocyte, Kupffer cell, Langerhans cell, microglia, hofbauer 
cell, mesangial cell, osteoclast, epitheloid cell. However, subsequent molecular and genetic 
analysis has confirmed their myeloid-derived lineage. Once the fetus matures into a newborn (and 
then adult), hematopoesis shifts from the liver and spleen to the bone marrow. Subsequent 
production of monoblasts, and therefore monocytes and macrophages, then occur from myeloid 
progenitor cells in the bone marrow. Also, although it was once believed that tissue-resident 
macrophages were entirely derived from hematopoetic cells and that their tissue reservoirs is 
replenished when hematopoiesis shifts to the bone marrow, recent evidence suggests that 
reservoirs of tissue-specific macrophages can be maintained through local self-proliferation
78
.  
There is recent consensus that both monocytes and macrophages could be broadly 
categorized into two different states: an activated and inflammatory state; and a resident and 
reparative state
79, 80
. The two states of monocytes are defined by surface markers; that could be 
easy detection by flow cytometry of peripheral blood. Inflammatory monocytes are larger and 
express CCR2 (denoted CCR2
+
) chemokine receptor, L-selectin, and high levels of Ly-6C (denoted 
Ly-6C
hi





) or L-selectin, but instead express the fractalkine receptor CX3CR1. Inflammatory 
monocytes normally represent 2-5% of circulating leukocytes, and they home rapidly to sites of 
inflammation largely because of their CCR2 receptors. Resident monocytes are less prevalent in 
the peripheral blood but they have a unique ability to migrate along the luminal surface of 
endothelial cells and patrol the vasculature. Both types of cells are derived from bone marrow 
monocytes but a splenic reservoir of both types of differentiated monocytes exists for rapid 
deployment when needed
45
. Just like their blood-borne originant, macrophages can exist in two 
polarized states.  







microbicidal activity, produce inflammatory cytokines, release matrix metalloproteinases, and 
respond to T-helper type I cytokines, primarily IFN-γ80. Two decades ago, Gordon et al, discovered 
that IL-4 induces macrophages to adopt a unique phenotype associated with the production of 
growth factors (PDGF and TGFβ), inhibition of metalloproteinase activity, and responsiveness to T-
helper type II cytokines, such as IL-4 and also IL-13
81
. These two subsets of macrophages were 
categorized as M1 or classically activated, and M2 or alternatively activated
82
. Specific markers of 
these two subsets have been described; two markers that represent the two subsets particularly 
well are inducible nitric oxide synthase (iNOS) and arginase
83
. Both these enzymes compete for 
arginine: iNOS converts arginine into nitric oxide, while arginase converts arginine into ornithine 
and urea. Conversion of arginine to NO is required for both inflammatory vasodilation and killing 
of microbes - two important key events that characterize the onset of inflammation. The arginase 
product ornithine is a precursor of proline, the second most common amino acid in collagen. As 
collagen is the primary constituent of extracellular matrices, ensuring its consistent supply is 
critically important during the proliferative and remodeling phase of inflammation. Therefore, the 
two subsets of macrophages have been classified as M1 macrophages, which are inflammatory 
and destructive while the M2 macrophages are pro-resolving and reparative.  












) differentiate into M2 macrophages
84
. Nevertheless, this 
segregation is intensely debated and recent evidence suggests otherwise. Detailed tracking 
studies involving the monocytes and macrophages in blood and in tissue provide strong evidence 
that during the onset of inflammation inflammatory monocytes are recruited to afflicted tissue 
where they participate in pathogen neutralization before transforming into resting monocytes 
that then mediate the resolution of inflammation
78







monocytes differentiate fully into reparative macrophages during the proliferative and 
remodeling phase of inflammation. These reparative macrophages display a combination of 
markers in between the polarized M1 and M2 definitions however. While this is somewhat 
conflicting, it is important to qualify that M1 and M2 phenotypes are largely defined by their in 
vitro characteristics. Stimulation with recombinant IFNγ or IL-4 can induce M1 and M2 
polarization in cultured macrophages, and specific isolated in vivo populations of macrophages 
can variously display M1 or M2 markers
80
. However, macrophages are highly plastic cells that are 
capable of shifting between the extreme categories of M1 and M2 in a heterogenous continuum 
in vivo, and it is being increasing recognized that macrophages assume a wide spectrum of 
phenotypic characteristics with M1 and M2 representing the two most polarized states
84
.  
Several studies have shown that transplantation of exogenous monocytes and 
macrophages promote tissue healing and repair in models of tissue infection and injury
85
. 
Because these studies use different types of monocytes or macrophages, the extent of protection 
observed is variable. Thus improving the definition of monocyte and macrophage subsets could 
help in developing more targeted interventions. An area of particularly urgent clinical need is 
therapeutic revascularization. Monocytes and macrophages are necessary for revascularization, 
and their supplementation can enhance revascularization. Loss-of-function studies in which 
monocytes or macrophages were depleted by pharmaceutical intervention or genetic 
manipulation before ischemia have shown significant defects in revascularization. In comparable 
gain-of-function studies wherein monocytes or macrophages were supplemented before and or 
after ischemia, usually by intravenous injection, marked improvements in revascularization were 
demonstrated. The consensus is that monocytes and macrophages improve revascularization via 
three main mechanisms
86
: (1) generation of arteriogenic and angiogenic growth factors and 







into the structural constituents of the vascular wall. Given the highly heterogenous and plastic 
nature of these cells, these three mechanisms are hardly surprising in the diversity and reach. 
Finally, the evidence supporting that the notion that monocyte and macrophage transplantation 
enhances revascularization is not entirely derived from laboratory animals, as transplantation of 
monocytes or macrophages have also demonstrated improvements in revascularization in human 
clinical trials as well
85
. Nevertheless, the two important questions remain unanswered: What 
subsets of monocyte or macrophage enhance revascularization? And what are their most effective 
secreted mediators that promote revascularization?  
The first question has already been extensively addressed, though the answer is 
ambiguous and slightly anti-climactic. Many subsets of monocyte or macrophage have the ability 
to improve revascularization. However, since there is variability in disease model, method of cell 
collection, and time of supplementation, the efficacy of these subsets cannot be directly 
compared
85
. Monocytes and macrophages exist in many different body depots: blood, spleen, 
peritoneum, and bone marrow. Given their highly plastic nature, the cells that populate these 
depots are heterogenous and exist on a shifting continuum of subsets. The method of collection, 
purification and amplification of these cell depots generates further variability. Furthermore, the 
time point(s) at which this heterogenous mix of cells is supplemented, in relation to the original 
occlusive injury, can have significant impact on outcome. One biomedical company, Aastrom 
Biosciences, is currently testing its proprietary monocyte and macrophage mixture, ixmyelocel-T, 
for treatment of critical limb ischemia (CLI) in phase 3 clinical trials
87
. Preliminary data from earlier 
trials suggest there could be some reduction in adverse CLI outcomes, indicating that 
revascularization-enhancing monocyte and macrophage cell therapy has promising clinical 
potential. The final verdict must wait until the estimated study completion date in March 2015. 







requires autologous donor cells, subject to isolated cell variability, and poses immunogenicity or 
contamination risks85. Whenever possible, a pharmaceutical alternative is more effective and less 
fickle. Therefore the second question of most effective pharmaceutically adaptable 
revascularization-enhancing mediator is very pressing.  
VEGF and FGF are critical mediators of angiogenesis and they are small proteins, 
recommending them as obvious revascularization-enhancing candidates for pharmaceutical 
adaptation
72
. Various forms of VEGF and FGF were developed: recombinant protein, naked DNA, 
gene-containing plasmid. And various methods of administration were tested: intravenous, 
intramuscular, and intracoronary. Thus far, no combination of approaches has yielded an FDA-
approved drug. Many other secreted mediators have been the subject of candidate drug trials, 
but none has yet to be approved.  
One family of secreted mediators vying for pharmaceutical candidacy in the enhancement 
of post-ischemia revascularization is the pro-resolving lipid mediators. Traditional prostaglandins 
are already employed in the clinic for various vascular anomalies: PGE1 as alprostadil; PGE2 as 
dinoprostone; PGF2α as dinoprost; and PGI2 as epoprostenol
40
. Thus pro-resolving lipid 
mediators have reliable precedents set for its translation. Furthermore, recent studies have directly 
tested its potential for revascularization enhancement. In a rat model of myocardial ischemia, 
resolvin E1 (RvE1) administration thirty minutes after ischemia attenuated cardiac infarct size
88
. In 
a mouse model of renal ischemia-reperfusion injury, RvD1 treated mice also experienced 
attenuated drops in kidney function
89
. What remains unclear though, are the specific mechanisms 
by which resolvins enhance revascularization. Another two key questions remain: what are the 
cells that produce these revascularization-enhancing pro-resolving lipid mediators? and what are 

















 Impaired tissue perfusion is a pathologic feature of many prevalent chronic diseases, 
including peripheral artery disease and diabetes, which can precipitate tissue necrosis or limb 
amputation90. Several clinical strategies have been designed to increase the revascularization of 
ischemic tissue in these diseases. Treatments include endovascular angioplasty, bypass grafting, 
and delivery of specific angiogenic agents (VEGF, bFGF, GM-CSF). Recently, cell therapy involving 
the autologous supplementation of exogenously amplified mononuclear or progenitor cells, have 
been used to promote revascularization
87
. Although often successful, these therapies have limited 
efficacy in part because they do not address the underlying chronic inflammation, which is often 
the primary feature of diseases involving impaired tissue perfusion. Furthermore, angiogenic 
agents are often also mitogenic and therefore possess the ability to exacerbate the underlying 
chronic inflammation
91
. Therefore new therapeutic candidates are needed to promote 
revascularization of ischemic tissue and concomitantly stimulate the resolution of chronic 
inflammation.  
The resolution of inflammation is an essential process within an animal’s self-regenerative 
ability to address injuries incurred during their lives. While the form of injury, pathogenic 
infection, traumatic wounding, ischemic damage, varies, a broadly common program of biological 
processes occurs in response. Inflammation is the initiating process wherein leukocytes infiltrate 
from the blood to contain the injury and remove damaged tissue. Resolution follows 
inflammation; structural and vascular cells migrate to create a provisional tissue scaffold and 
restore blood supply. The final process of wound healing is regeneration, where the initial 
structural components are consolidated and repopulated. Since wound healing begins with 
inflammation, the timely conclusion of this phase is essential. The prevailing dogma holds that 







emerging evidence suggests that the resolution of inflammation is an active process, orchestrated 
by in part by lipid mediators and involving a “pro-resolving program” that counteracts ongoing 
inflammation
43
. Due to the leading role of inflammation in the wound healing process, pro-
resolving lipid mediators are thus hypothesized to be important proponents of the return to 
homeostasis. These pro-resolving lipid mediators are generated during inflammation by 
leukocytes and have direct actions on monocytes/macrophages (stimulating phagocytosis) and 
endothelial cells (nitric oxide production)
55
. Other investigators report that resolvins are generated 
during kidney model of ischemic injury and 12/15 lipoxygenase KO mice (an enzyme involved in 
resolvin synthesis) experience impaired recovery from hind limb ischemia injury
92
. Therefore the 
resolvin pathway is directly implicated in the neovascularization process of wound healing. 
In this series of investigations, I hypothesize that during the wound healing process, 
leukocyte-derived pro-resolving lipid mediators promote tissue revascularization by stimulating 
arteriogenesis and angiogenesis. To test this hypothesis, we will assess whether exogenous 
delivery of pro-resolving lipid mediator resolvin D2 (RvD2) will enhance revascularization using a 
murine model of hind limb ischemia. In ischemic limbs, we will assess the recovery of limb blood 
flow by laser Doppler perfusion imaging and measure increases in arteriogenesis and 
angiogenesis by Microfil injection and micro-computed tomography of hind limbs. To examine 
the cellular biosynthesis of RvD2 during revascularization, we will determine whether RvD2 is 
generated during revascularization, and whether monocytes and macrophages produce RvD2. 
Finally, to provide evidence of RvD2-stimulated arteriogenesis and angiogenesis, we will examine 
RvD2-induced changes in gene transcription in monocytes, macrophages and endothelial cells. 
We will use the Matrigel plug assay to assess the direct angiogenicity of RvD2 in vivo. To identify 
the endothelial effects of RvD2, we will measure the stimulation of endothelial migration and 







resolving lipid mediators play a role in wound revascularization. Results of these studies could 
form the basis for the development of novel therapeutics aimed at improving revascularization in 
major clinical occlusive crises such as myocardial infarction, stroke and critical limb ischemia, and 
















RESOLVIN D2 ENHANCES POST-OCCLUSION REVASCULARIZATION 
Introduction 
Inflammation is a dynamic process mediated by quorums of danger sensors, secreted 
mediators, and resident and infiltrating cells. It can combat a remarkably diverse armada of 
pathogenic invaders, and it can redress a wide spectrum of traumatic or ischemic injuries. 
Unfortunately, inflammation can also produce collateral damage and it may not always promote a 
full restoration of function. The improper sensing of benign antigens, followed by an exaggerated 
inflammatory response, underlies the mortality of anaphylactic reactions
7
. Deep cutaneous 
wounds do not heal completely; they are covered by a reduced thickness fibrotic scar
7
. Often 
inflammation does not resolve promptly, perpetuating a chronically active state
7
. Prominent 
clinical examples of this unremitting state include autoimmune diseases, atherosclerosis, diabetes, 
Alzheimer’s disease, lung fibrosis, and cancer. In essence inflammation prevents infections and 
promotes healing, but if the process becomes deranged it can cause injury and disease itself.  
The intuitive approach to combat unresolved inflammation clinically would be to inhibit 
further escalation of inflammation. For decades, medical treatments focused on inhibiting 
inflammation via agents that antagonize enzymes, receptors, genes or cytokines responsible for 
its propagation. For example, anti-histamines block histamine receptors to quell allergic 
reactions
93
. Non-steroidal anti-inflammatory drugs block COX-1 and COX-2-dependent 
production of prostaglandins
94
. Synthetic glucocorticoids interfere with pro-inflammatory gene 
expression and directly induce apoptosis in lymphocytes
95







monoclonal antibody therapies that neutralize pro-inflammatory TNF-α and IL-1β, respectively96. 
Thus, agents that block the inflammation are some of the most commonly used drugs in clinical 
medicine. Nevertheless, even though these drugs can be highly effective in acute situations, 
blocking inflammation chronically carries significant adverse effects. Prolonged NSAID use can 
cause gastric ulcers and liver damage
97
. Selective COX-2 inhibitors can actually increase 
cardiovascular mortality
98
. Glucocorticoids cause lipodystrophy and induce a dangerously 
immunocompromised state
99
.  As a result, new and alternative strategies for modulating the 
inflammatory response are being sought actively. One novel approach is to promote resolution of 
inflammation (i.e., agonism) rather than simply shutting it down (i.e, antagonism).  
 Polyunsaturated fatty acids have been extensively studied for potential resolution-
promoting actions and the recent discovery of pro-resolution lipid mediators derived from ω-3 
PUFAs has established a new class of compounds with therapeutic potential. Decades of human 
trials have already made a strong case for further promotion of cardiovascular health by ω-3 
PUFAs. In 1956, Sinclair postulated that low rates of atherosclerosis in the Canadian Inuit were a 
result of their high consumption of marine fat
100
. A much more systematic series of studies were 
completed by Bang and Dyerberg in 1970s across the bay in Greenland Inuits
101, 102
. They found 
that while the total fat percentage of Greenland Inuit diets were nearly identical to Danish diets, 
the Inuit consumed a much higher percentage of ω-3 fatty acids while the Danish consumed 
more saturated fats. The higher consumption of ω-3 fatty acids (DHA and EPA) corresponded to 
higher composition of ω-3 fatty acids in Inuit blood platelets. Remarkably, these Inuit also had 
significantly lower plasma triglycerides and higher high-density lipoprotein. In a morbidity survey 
spanning 25 years in 1800 Inuit, the incidence of myocardial infarction was ten fold lower than the 
Danish population. Across the world, Japanese Okinawans with similar ω-3 diets also had low 
rates of cardiovascular disease
103







Reinfarction Trial (DART) in 1989 found a decrease in both cardiovascular disease-related death 
and all-cause mortality in post-MI non-diabetic men consuming ~300g of fatty fish a week104. 
Unfortunately, large populations of humans live far from ocean coasts and do not consume a high 
ω-3 fish diet. Fortunately, supplementation of ω-3 fatty acids in pill form is much easier. Thus the 
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) Prevenzione trial, 
enrolled over 11,000 patients with a history of myocardial infarction, and in the active treatment 
group, demonstrated reduced risk of cardiovascular death in those consuming 850-882mg of EPA 
and DHA per day
105
. More recently, the GISSI–heart failure trial further concluded that fish oil 
supplementation decreased mortality in heart failure patients
106
. Although the DART and GISSI 
trials are the two largest clinical trials involving ω-3 fatty acids, many other smaller trials with 
different test criteria and endpoints have also been performed. A meta-analysis of their combined 
results found substantial variation in total mortality and no evidence of substantial benefit of ω-3 
fatty acids on combined cardiovascular mortality
107
. While this conclusion is discouraging, it is 
important to note the large numbers of confounding factors, such as study size, treatment 
methodology, and patient compliance can obfuscate results and cloud conclusions. Unlike the 
equivocal conclusions of the human trials, an unequivocal solution is to further research into the 
mechanisms underlying the beneficial cardiovascular effects of ω-3 fatty acids.  
The ω-3 fatty acids EPA and DHA are bioactive and may directly contribute to 
cardiovascular death reduction, but they are also substrates for cyclooxygenases and 
lipoxygenases like the ω-6 arachidonic acid (AA). Therefore the health benefits of ω-3 fatty acids 
may not be related to direct actions, but are mediated through the actions of their metabolites. 
For example, EPA can be converted to 3-series prostaglandins and 5-series leukotrienes that are 
less biologically potent than their AA counterparts
108
. When they flux through the normal 







though substrate competition.  The physiological result is that in a high ω-3 diet, with the same 
level of other inflammatory stimuli and mediators, less potent inflammatory responses are 
generated. As described in the previous chapter, this reduced response is not always detrimental. 
In fact during fetal cutaneous wound healing, the immature mast cell response allows the wound 
to heal without scarring
109
. The recently created fat-1 transgenic mouse, which expressed a 
desaturase enzyme enabling endogenous ω-6 to ω-3 fatty acid conversion, is protected from 
inflammatory pathologies such as colitis and asthma
110
. So far, this evidence suggests that ω-3 
fatty acids possess mostly anti-inflammatory properties. However, the discovery of E-series and D-
series of resolvins
111
, coupled with existing knowledge of the anti-inflammatory but also pro-
resolving actions of lipoxin A4 (derived from AA), has led to the proposal that local biosynthesis 
of bioactive lipid mediators could underlie some of the health-benefitting immunomodulatory 
effects of ω-3 fatty acids. 
Resolvins have been extensively studied, and their basic characteristics have been widely 
reported, more immunomodulatory actions are being described. Recent work has identified the 
biosynthetic pathway (to be discussed in the next chapter) and the cellular receptors for some 
resolvins
112
. Is has been shown that EPA-derived RvE1 binds to ChemR23, a GPCR with about 36% 
sequence homology to the lipoxin A4 receptor (ALX). It also binds to BLT1, another GPCR that 
binds also LTB4. Interestingly, RvE1 acts as an inverse agonist of BLT1, preventing the 
inflammatory actions of LTB4. The DHA-derived RvD1 binds to ALX and GPR32 receptors in 
humans
113
. Stimulation of human macrophages with RvD1 enhanced their phagocytosis of 
apoptotic neutrophils and yeast zymosan. RNAi knockdown of either receptor decreased 
phagocytosis rates and overexpression of each further enhanced phagocytosis rates. Many of the 
biological actions of RvE1 are summarized in Chapter 1. RvD1 also possess potent bioactivity
114
. In 







and adherence to endothelial cells. During mouse peritonitis, RvD1 can modulate microRNAs, 
increasing miR-21, miR-146b and miR-219 expression while decreasing miR-208a. It has also been 
shown that RvD1, like RvE1, can block inflammatory pain, but antagonizes a different set of 
transient receptor potential channels: TRPV3, TRPV4 and TRPA1. In a mouse model of obesity-
induced steatohepatitis, RvD1 administration was able to increase adiponectin expression, reduce 
macrophage infiltration, skew existing macrophages into a M2 phenotype, and reduce expression 
of COX2, IL1β, IL-6 and CCR7 mRNA
115
. In a complementary obesity study by our research group, 
RvD1 treatment of leptin receptor-deficient diabetic mice increased insulin sensitivity, adiponectin 
levels and insulin-stimulated Akt phosphorylation in adipose tissue. RvD1 also reduced crown-like 
structures, granuloma-resembling masses of apoptosis adipocytes phagocytosing M1 
macrophages, and instead increased the presence of M2 macrophages in adipose tissue. In a 
follow-up study by our group, RvD1 treatment attenuated the chronic inflammatory diabetic state 
by reducing accumulation of apoptotic thymocytes, enhancing the resolution of acute peritonitis, 
and stimulating Fc receptor-mediated macrophage phagocytosis
116
. Additionally, we documented 
decreased production of resolvin-precursors in skin wounds of these diabetic mice. We found that 
when RvD1 was topically applied to wounds, wound closure accelerated and fewer apoptotic cells 
and macrophages accumulated. As defective wound healing is a serious concern in diabetics, a 
topical healing accelerator represents an attractive therapeutic strategy. Finally, given the pressing 
global obesity epidemic
117
, and the extant cardiovascular crisis, RvD1 might be a promising 
candidate for pharmaceutical therapy to resolve inflammation and promote resolution.   
Resolvin D1 was the first D-series resolvins to be described. Since its discovery, other D-
series resolvins have been characterized. Resolvin D2 (RvD2) is a regioisomer of RvD1 that is also 
present during the resolution phase of inflammation
55
. In the mouse acute peritonitis model, 







of zymosan particles. In a mouse cecal-ligation sepsis model, RvD2-treated mice experienced 
lesser microbial spillover into the peripheral blood and peritoneum, and experienced greater 
overall survival rates. Peritoneal neutrophil numbers, as well as inflammatory mediators TNF-α, IL-
1β, IL-6, IL-23, IL-17, PGE2 and LTB4, were decreased as well. Additionally, as previously 
mentioned, while RvD2 has no direct microbicidal effect like NO, it nevertheless enhanced the 
ability of leukocytes to contain the leaked bacteria. Some of these outcomes resemble RvD1-
stimulated effects, others are unique. Especially novel and intriguing are its vascular actions. In the 
exposed mouse cremaster muscle microcirulatory model, RvD2 reduced platelet activating factor-
stimulated neutrophil adherence and extravasation. Further addition of the NO synthase inhibitor, 
L-NAME, restored the basal effects of PAF on neutrophils. In a separate in vitro experiment, RvD2 
also stimulated NO generation by human umbilical vein endothelial cells. Collectively, RvD2 has a 
distinctive assortment of immunomodulatory and vascular actions. Coincidently, these actions 
intersect with the immunovascular process of arteriogenesis and angiogenesis after tissue injury. 
Because ω-3 fatty acid supplementation can reduce adverse cardiovascular outcomes, and ω-3 
fatty acids can be metabolized into RvD2, it is likely that the cardiovascular benefits of ω-3 fatty 
acid supplementation may be mediated by the immunovascular effects of RvD2.  
 Critical limb ischemia is an adverse cardiovascular outcome, and a serious clinical problem 
with inadequate treatment options
90
. CLI occurs in humans when an acute thrombus or heart-
derived embolus develops in the lower limb and causes a sudden decrease in perfusion that 
threatens limb viability. Cather-directed revascularization can treat marginally threatened limbs 
with recent occlusions and surgical revascularization is performed on acutely threatened limbs. 
Even with intervention, death and complication rates are high. Ten to fifteen percent of patients 
require limb amputation and fifteen to twenty percent die within one year of presentation. The 







caused by atherosclerosis118. It affects around 10 million Americans. Most patients are elderly and 
experience intermittent leg pain and persistent soreness, and their disease can be exacerbated by 
smoking and diabetes. With incidences of obesity, diabetes, and cardiovascular disease increasing 
across the globe, more therapies to address critical limb ischemia are urgently needed.  
The mouse hind limb ischemia model is directly correlated to human critical limb 
ischemia (CLI), and therefore has been a convenient platform to study the cellular, molecular and 
genetic mechanisms involved in the arteriogenic and angiogenic recovery of perfusion
119
. It is also 
a great platform to study new compounds with therapeutic potential and to examine potential 
benefits of RvD2 immunovascular modulation. In this model, the femoral artery and vein of the 
right hind limb is ligated and severed just inferior to the external iliac artery and deep to the 
inguinal ligament. The mouse is then allowed to recover over the course of two weeks to monitor 
restoration of blood perfusion to this damaged limb. Immediately after femoral artery and vein 
ligature, perfusion recovery in the upper mouse limb is predominantly due to arteriogenesis. A 
few days later, hypoxia in the lower limb stimulates angiogenesis, which becomes the primary 
avenue for perfusion recovery. Overall recovery by both processes can be monitored 
longitudinally by laser Doppler perfusion imaging (LDPI), which aims a laser at the limb surface 
and correlates flow-induced light scatter to quantitate perfusion
120
. Animals can be euthanized for 
histology, Microfil silicone pigment perfusion, and micro computed tomography (microCT) to 
examine gross vascular changes
121
. Therefore, we used the mouse hind limb ischemia model to 
evaluate the effects of the pro-resolving lipid mediator RvD2 on arteriogenic and angiogenic 
perfusion recovery following ischemia. LDPI was used to quantitate these effects, and we 
measured an increase in perfusion recovery by RvD2. We also evaluated overall vascular volume 
changes with Microfil vascular casting and microCT quantitation. Finally, we examined 







sections119. From these experiments we collected evidence that supports a beneficial role for pro-
resolution RvD2 during revascularization after arterial occlusion.  
 
Experimental procedures 
Animals and reagents-Male C57B/6J mice 8-10 weeks of age were purchased from Jackson 
Laboratories. All animal procedures were approved by the University of Louisville Institutional 
Animal Care and Use Committee (no. 11093). Resolvin D2 (RvD2) (7S,16R,17S-trihydroxy-4Z,8E,
10Z,12E,14E,19Z-docosahexaenoic acid) was purchased from Cayman Chemical (Ann Arbor, MI).  
 
Hind limb ischemia model-We used two different models of ischemia, a severe model involving 
a more superior ligation site, and a more mild model involving a more inferior ligation site. For 
the severe model, the mouse subject was anesthetized on the surgical surface with 3% isoflurane 
in 2L/min oxygen. The right limb was then denuded by depilatory cream and sterilized by ethanol 
wipes. A 5mm vertical skin incision was made lateral to the abdomen superficial to the inguinal 
ligament. The inguinal fat pad was separated from the peritoneal lining to reveal the proximal 
femoral artery branching from the external iliac artery. The femoral artery and vein were then 
separated from their protective sheath and two ligatures 2mm apart were made. Vessels were 
then severed between the ligatures and the skin incision was closed with two discontinuous 
sutures and bonded with n-butyl-ester cyanoacrylate. For the mild model, mice were anesthetized 
and denuded. A 3mm horizontal skin incision was made superficial to the medial right knee. The 
branch point where the femoral artery bifurcates into the saphenous artery and popliteal artery 
was exposed from its membrane sheath. The accompanying nerve was moved aside and a 
ligature was placed around the saphenous artery and vein immediately proximal to the femoral 







severed. The skin was then closed with sutures and cyanoacrylate. Sham operated mice were 
opened, dissected, and closed, without vessel ligature. Twenty-four hours after surgery, mice were 
injected with either 0.9% saline vehicle (100 µl) or resolvin D2 in vehicle (RvD2; 100 µl; 4µg/kg 
body weight) subcutaneously just superficial to the ligation site. 
 
Laser Doppler perfusion imaging-Mouse limbs analyzed by LDPI were fully denuded a day prior 
below the midline to allow the scanning laser to penetrate below the skin. The mice were then 
anesthetized with isoflurane and placed on its dorsal surface on a dark scanning surface above a 
40°C heat pad. Perfusion of the ventral surface of both right and left hind limbs was measured 
with a PeriScan PIM 2 laser Doppler device (Perimed). Images were acquired one, seven and 
fourteen days after ligation. After acquisition, color-binned images of the mouse limbs were 
imported into ImageJ, and areas of blue, green and red in the region of interest (ROI) spanning 
the entire hind limb was enumerated. The value for the right limb was then normalized to the left 
(nonischemic) limb to calculate the % recovery of blood perfusion.  
 
Vascular casting and microCT-Mice were anticoagulated with 10µL intraperitoneal injection of 
1000 units/mL of heparin and sedated with 10µL of pentobarbital.  Their hearts were then 
cannulated with a 15g needle perfused systemically at 5mL/min with 10mL of 100 μM adenosine, 
10 μM nitroprusside and 0.05 % wt/vol bovine serum album. Undiluted Microfil was mixed with 
hardening solution, perfused, and allowed to solidify. The entire lower body was de-skinned and 
placed in formalin for 24 h and Cal EX II for 48 h to fix and decalcify. Samples were then imaged 
with a MicroCAT II (Siemens) scanning at 80 kVp and 500 µA, with 2x2 binning for a pixel 
resolution of 1024x1024 with 34µM voxel sizes. After thresholding of soft tissue, casted blood 







imaging of Microfil casted limbs, harvested limbs were places in successively higher solutions of 
glycerol (40%, 60%, 80%, 100%, solution changed every 24 hours) and imaged with a digital CCD 
camera (Nikon).  
 
Histology-For histological analysis, mice were euthanized and their limbs were dissected. The 
upper limb semitendinosus, semimembranosus and biceps femoris (hamstring) muscles and the 
lower limb gastrocnemius muscle were excised and fixed in formalin and paraffin embedded. 
Three transverse cross sections of the muscles were mounted per slide and 2 slides were amassed 
per mouse. Gross examination of tissue injury was performed on hematoxylin and eosin (H&E) 
stained sections. The number of myocytes with centrally located nuclei indicates muscle 
regeneration and this marker was used to assess the extent of limb damage and recovery with 
RvD2 treatment
122
. Five to ten low power fields were examined and the total number of myocytes 
and myocytes with centrally located nuclei were enumerated.   
 
Data analysis, statistics-All reported data are reported as means ± SEM. For all statistical 
analysis, Prism 6 (GraphPad) was used. Data were analyzed by one-way or two-way ANOVA 
followed Bonferroni post-tests for multiple groups, or unpaired two-tail Student’s t test for direct 
comparisons. A p value less than 0.05 was considered significant.  
 
Results 
Limb perfusion is enhanced in ischemic limbs of mice treated with RvD2-To determine 
whether pro-resolving lipid mediators are capable of enhancing post-ischemia revascularization, 
we induced severe hind limb ischemia in eight week old male C57B/6J mice via ligature of their 







injections (100µL volume, 4µg/kg) were commenced 24 h after surgery and continued daily for 14 
days. We waited 24 hours for inflammation to develop in the ischemic limb and then introduced 
RvD2 on the first day post-surgery.  The extent of perfusion recovery in RvD2-treated animals was 
identical to saline-vehicle treated control animals at 8% (Figure 1). By day 7, the recovery of RvD2-
treated animals had risen to 46% while control animals lingered at 20%. At the last scan on Day 
14, the ischemic limbs of RvD2-treated animals had recovered 64% of original perfusion, while in 
control animal limbs perfusion was restored only to 29%. Since RvD2-treated HLI-mice 
demonstrated an increased rate of perfusion recovery, the experiment was terminated at day 14. 
Overall, the absolute increase in severe-model ischemic limb perfusion recovery in vehicle-treated 
mice, as measured by LDPI, is 21% (29%-8%), in RvD2-treated mice, it is 56% (64%-8%). From 
these data we concluded that RvD2 enhanced restoration of LDPI-measured blood flow in the 
mouse HLI model. 
 
RvD2 enhances arteriogenesis in mice undergoing HLI-To obtain a stereoscopic 
understanding of RvD2-enhanced revascularization of mouse hind limb, we used Microfil, a 
radiocontrast-infused silicone elastomer, to cast the entire mouse vasculature and examine limb 
vascular volumes by microCT. We casted severe-HLI mice seven days after ligation and compared 
effects of vehicle versus RvD2 treatment. Due to the three-dimensional projection of voxels, a 
stereoscopic view of the entire lower mouse limb allowed us to visualize an extensive network of 
tortuous arteriogenic collaterals in the ischemic side of limbs. After quantitation of the entire limb 
voxels, we found that vehicle-treated mice were able to restore 89% blood perfusion in the 
ischemic limb compared with the nonischemic limb (Figure 2). RvD2-treated mice were able to 
restore 100% blood perfusion. We also casted mild-HLI mice three days after surgical occlusion 







while RvD2 treated mice recovered 92% (Figure 3B). We also clarified the mild-HLI limb tissue to 
directly visualize the restoration of perfusion. Vehicle-treated mice limbs were not robustly 
perfused by Microfil and retained red coloration. RvD2-treated mice limbs were more extensively 
perfused by Microfil, and displayed pathognomonic signs of tortuous arteriogenic collateral 
arterioles (Figure 3A).  
 
RvD2 increases number of regenerating myocytes-We performed histopathological analysis of 
mouse hind limb muscles to determine whether the extent of enhanced perfusion by RvD2 
resulted in improved tissue repair. Necrotic muscle can be identified using H&E staining to 
highlight the presence of basophilic infiltrated leukocytes, hypercontracted myofibres, and 
degenerating myocytes with fragmented sarcoplasm. Regenerating muscle can be identified by 
the presence of small activated myoblasts with plump myofibres with centrally located nuclei. 
Since undamaged myocytes contain peripherally located nuclei, and dark blue hemalum-stained 
nuclei are easy to identify, we quantified the difference between RvD2-treated and vehicle-treated 
ischemic hind limbs by counting central versus peripheral nuclei in H&E sections of the hamstring 
muscles (Figure 4). We harvested limb muscles (hamstring) at two weeks after induction of 
ischemia, and found a higher percentage of regenerating myocytes in sections of RvD2-treated 
mice compared with vehicle-treated mice. As there was no ischemia in sham-operated animals, 
we did not find any centrally located nuclei in either vehicle-treated or RvD2-treated sham 
animals. Our overall histological analysis found qualitative evidence of reduced leukocyte 









Figure 1: Laser Doppler perfusion imaging (LDPI) of mouse hind limb. Representative LDPI images 
and quantitation of vehicle or RvD2-treated mice at day 1, 7 and 14 after severe model of 
proximal femoral artery and vein ligation. The red box indicates ischemic region of interest (ROI). 
Percent recovery of blood flow is calculated as the number of red and green pixels in the ischemic 






































Figure 2: MicroCT of Microfil-casted limbs, severe HLI model. Representative microCT images and 
quantitation of Microfil-casted limbs of vehicle or RvD2-treated severe HLI model limbs 7 days 
after surgical ligation. Dotted line indicates superior site of ligation, arrows refer to tortuous 


























































Figure 3: Whole mount and microCT images of Microfil-casted limbs, mild HLI model. (A) 
Representative whole mount images glycerol-clarified Microfil-casted limbs of vehicle or RvD2-
treated mild HLI model limbs 3 days after surgical ligation. Arrows refer to tortuous arteriogenic 













































































Figure 4: Histology of hamstring muscles, severe model of hind limb ischemia. Hematoxylin and 
eosin stained paraffin sections of vehicle and RvD2-treated right hamstring muscles fourteen days 
after severe model of HLI. Sham-surgery controls included for comparison. Regenerating 
myocytes with centrally located nuclei were enumerated as a percentage of total myocytes. 












































































In this study, we have provided evidence that pro-resolving lipid mediator resolvin D2 can 
enhance the blood perfusion recovery of femoral artery and vein-occluded ischemic mouse hind 
limbs. We report longitudinal data over a two week period using LDPI and endpoint data at seven 
days using Microfil-microCT with a severe model of hind limb ischemia. We also provide 
histologic evidence of RvD2-stimulated muscle regeneration in the hamstring muscles, and 
corroborated RvD2 efficacy in a more mild model of hind limb ischemia.  
We found that RvD2 in highly effective in enhancing post-ischemia revascularization, and 
its efficacy compares very favorably with other reported therapeutic strategies. LDPI is the gold 
standard upon which all mouse HLI studies are quantitated
119
. In our severe HLI model, we 
obtained a 56% absolute increase in ischemic limb perfusion after 14 days. In a study by other 
investigators, daily administration of plasminogen activator inhibitor-1 after ischemia induction 
produced an absolute perfusion recovery of 25%. In another study, an infusion of endothelial 
progenitor cells (EPCs) 3-6 hours after ischemia improved perfusion by 30% fourteen days later
123
. 
In another study, the intramuscular electroporation of a human VEGF-containing plasmid 
increased 14-day limb perfusion by 35%
124
. Combining the VEGF plasmid with a hepatocyte 
growth factor (HGF)-containing plasmid yielded a perfusion increase of 50% at day 14. Finally, in a 
BMX-kinase transgenic mouse, increased Tie-2 promoter-driven overexpression of BMX promoted 
limb perfusion recovery by 80% at day 14
125
. While impressive, these other studies have major 
caveats for therapeutic translation. The BMX kinase study produced impressive results, but there 
are currently no drugs that approximate the transgenic mouse model by stimulating BMX kinase 
overexpression. VEGF and other growth factor therapies have also proven auspicious in pre-
clinical studies, but in clinical trials no consistently efficacious therapeutic program has been 







shown promise in pre-clinical studies, and the macrophage cocktail Ixmyelocel-T is currently 
progressing in phase 3 clinical trials, but the overall process treatment process is lengthy (months) 
and the cocktail is not chemically defined.  
In comparison with other interventions, RvD2 possesses many advantages as a therapeutic and 
pharmaceutical candidate. RvD2-therapy does not involve any germline modifications. The 
absolute efficacy is higher than both EPC infusion and growth factor therapy. Also, RvD2 is a 
singular endogenous compound that can be synthesized artificially by total organic synthesis, and 
is therefore chemically defined. Finally, RvD2 is efficacious in enhancing perfusion recovery in a 
clinically feasible and therapeutically relevant manner, because we could observe a beneficial 
effect even when administered 24 h after initial ischemia. Patients presenting with coronary artery 
occlusion or critical limb ischemia would not need to be preemptively treated with RvD2 for 
therapeutic effect. Although given the other beneficial effects of pro-resolving lipid mediators in 
diabetes and ω-3 supplementation, perhaps preemptive pro-resolution therapy may be a good 
strategy. Nevertheless, many important translational questions about the use of RvD2 remain. For 
instance, what is the optimal dose of RvD2? Are daily injections necessary? Can RvD2 simply be 
administered topically? Given the promising evidence we have presented in this study, these 
translational questions can be addressed in the future.  
The Microfil casting and micro-computed tomography of revascularizing mouse limbs is a 
rigorous and holistic evaluation of perfusion recovery. One of the limitations of LDPI is the 
inability to penetrate deep into tissues, thus it can only measure blood flow in vessels that are 
near the surface of the skin
126
. The femoral artery is sufficiently superficial to be imaged by LDPI, 
but other arterioles and developing collaterals deeper in the muscles cannot be imaged. This is 
especially important in our severe HLI model, as our superior femoral ligation site disrupts blood 







inferior and thus only disrupts perfusion to lower limb and foot. Regardless of ligation site, 
Microfil casting of the limb vasculature is a versatile procedure. Once casted, limbs can be clarified 
with glycerol and blood vessels can be whole mounted and photographed. This allows 
investigators to appreciate visually the appearance of tortuous arterioles, which are hallmarks of 
arteriogenesis. Some studies have directly measured arteriole diameter in whole mount images, 
but this again captures only the surface vessels. Fortunately, the lead chromate radioconstrast in 
Microfil allows computed tomography to obtain a stereoscopic image of the entire limb 
vasculature. Initially we experienced difficulty distinguishing Microfilled blood vessels and mouse 
bone. This problem was addressed by decalcifying the bone with formic acid (CalEX II) and using 
more concentrated Microfil
121
. With additional thresholding of CT image intensities, we were able 
to obtain detailed images of the entire limb vascular tree and objectively quantitate the voxel 
volumes of nonischemic limb versus the ischemic limb using the powerful Analyze software. 
Therefore, rather than capturing only surface blood flow by LDPI, or measuring only select vessel 
diameters by micrograph, we quantified the entire limb vascular volume to rigorously and 
holistically evaluate RvD2 efficacy.  
 There are some weaknesses to the Microfil-microCT method. Microfil is infused as viscous 
fluid that hardens inside blood vessels after 30 min. However, the perfusion of Microfil through 
the vasculature is a stochastic process that is difficult to control. There is leakage of Microfil at the 
left ventricle infusion site, and the filling of large veins is often incomplete, leaving discontinuous 
sections of hardened Microfil. Additionally, arteriovenous anastomoses inhibit the ability to fill 
only outbound blood vessels, but not inbound vessels. The incomplete filling of some vessels and 
disproportionate filling of the large femoral veins was particularly troublesome during 
quantitation of three-dimensional microCT images, as visually appreciable differences in perfusion 







perform the mild model of hind limb ischemia. The lower ligation site allowed us to focus on a 
more distal portion of the limb vasculature to circumvent variations in large vein casting. 
Naturally, the less severe ischemia model results in faster perfusion recovery and thus we 
performed our casting-imaging procedure at an earlier time point to capture the effects of RvD2. 
Although this mild model addressed certain study limitations, the major limitation of Microfil-
microCT remained: resolution and detection limits impeded the ability to accurately measure 
capillary volume. Because increases in capillary volume are the primary contributions of 
angiogenesis to revascularization, our inability to measure capillary volume also precluded our 
ability to quantitate angiogenesis in the limbs. The resolution of microCT is very high (it can 
resolve 10 microns) but the primary handicap is the Microfil reagent
127
. Its high viscosity hinders 
capillary perfusion and its modest radiocontrast produces dim images that are difficult to 
distinguish from background. In the future, improved vascular casting and radiocontrast agents 
can be used to fill capillaries and allow direct measurement of angiogenesis.   
We performed only limited histology in our study. Other investigators stain limb muscle 
sections for leukocyte infiltrates and endothelial cells to quantitate tissue recovery after 
ischemia
119
. Although these methods are established and rigorous, our Microfil-microCT and flow 
cytometry (Chapter 4) methods are more objective and capture a larger sample size. We show a 
few representative histology images and performed rudimentary muscle regeneration analysis 
primarily to corroborate the other methods. We did not perform any functional testing or 
neurological status of the mouse limbs. Our study was focused on evaluating the extent of 
perfusion recovery. However, recovery of blood flow may not be directly proportional to 
restoration of function. Visually, RvD2-treated mice appear to have a larger range of motion than 
vehicle-treated mice as early as day 2 (data not shown). This is a subjective observation and in the 







functional status of their ischemic limb. Furthermore, CLI patients often experience pain in their 
limbs
90
. Other resolvins have already demonstrated direct inhibitory action on pain receptors. In 
the future, neurological testing on RvD2-treated mice limbs can confirm if RvD2 can also alleviate 
pain after ischemia. Coupled with its perfusion enhancing effects, any potential analgesic effect 
will only further enhance therapeutic efficacy.  
Finally, there are some limitations to the hind limb ischemia model in general. Although 
femoral artery ligation is anatomically relevant to human critical limb ischemia (CLI)
128
, the 
etiology and the severity are not. The most common cause of CLI, peripheral artery disease (PAD), 
was not a component of our HLI model and the mice in both of our HLI models eventually 
recovery full limb perfusion
90
. Outcomes of our mice models do not correspond to the mortality 
of CLI patients. The primary reason is that CLI patients are older and suffer other comorbidities 
whereas the mice we used were young and healthy. Other investigations with diabetic mice have 
demonstrated a revascularization defect like humans
129
. Therefore, to assess the efficacy of RvD2 
treatment more closely to humans, it will be important to evaluate the extent of perfusion 
recovery by RvD2 in mice with atherosclerosis or diabetes.  
 In summary, we have found in this study that RvD2 improves ischemic mouse hind limb 
blood flow recovery. We provide quantitative evidence by LDPI, Microfil-microCT, and histology. 
The efficacy of RvD2 compares favorably to other therapeutic candidates. We were unable to 
quantitate specifically angiogenesis and did not measure functional recovery. More studies will be 
necessary in the future to address these limitations and also examine a more clinically relevant 












MONOCYTES PRODUCE RESOLVIN D2 
Introduction 
 
Found in all living systems, polyunsaturated fatty acids display extraordinary diversity. 
Although many organisms possess desaturases to generate PUFAs de novo, most animals do not 
possess this ability and therefore must obtain PUFAs from their diet
31
. Although this need limits 
the PUFA heterogeneity in animals to mostly ω-6 and ω-3 PUFAs, their cis-configured double 
bonds allow the formation of a motely portfolio of peroxide, epoxide and hydroxide metabolites. 
Furthermore, animals have evolved complex enzyme systems to synthesize this wide collection of 
PUFA metabolites in a stepwise manner and employ them in a multiplicity of signaling tasks.  
This process begins with the incorporation of PUFAs into plasma membrane 
phospholipids and then their subsequent liberation upon stimulation. The incorporation of PUFAs 
into the plasma membrane phospholipids phosphatidylcholine, phosphatidylserine, 
phosphatidylinositol, and phosphatidylethanolamine, requires two enzymatic steps within the 
interstitium of membrane
31
.  First, the acyl-CoA synthetases form PUFA-CoA from free non-
esterified PUFA. Then, various lysophosphatide acyltransferases attach the PUFA-CoA to the sn-2 
position of phospholipids. The relative abundance of these PUFAs in the plasma membrane, 
mainly arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) 
differs between cells and organs. AA can comprise up to 25% of all fatty acids in T-cell 
membranes, whereas DHA is especially enriched in the brain
130
.  Although the PUFA content can 







PUFAs cluster in signaling islands or lipid rafts. However, the signaling functions of these lipids 
begin after their liberation from the phospholipid backbone by the phospholipase A2 (PLA2) 
family of enzymes
131
. There are here many families of PLA2 enzymes: intracellular cPLA2 and iPLA2 
families and the extracellular sPLA2 family. The main role of cPLA2 is initiation of PUFA 
metabolism, the main role of iPLA2 is maintaining membrane homeostasis, and the main role of 
sPLA2 is modulating extracellular phospholipids. Group IVA cPLA2α is the prototypic PLA2, it is the 
central regulator of PUFA release from the sn-2 position of membrane phospholipids. The gene 
encoding this lipase is located on chromosome 1q25, next to the COX 2 gene. While cPLA2α is 
constitutively expressed in most cells and tissues, inflammatory mediators or reparative growth 
factors can regulate cPLA2α gene translation and protein phosphorylation
132
. After expression, 
cPLA2α remains in the cytoplasm until an intracellular influx of calcium increases its affinity for 
specific membrane phospholipids by interacting with the C2 domain of the protein.  This results in 
the translocation of the enzyme to the plasma membrane where it catalyzes the liberation of 
PUFAs esterified to phospholipids.  
The PUFAs liberated from the membrane are metabolized by various enzymes, including 
the cyclooxygenases, lipoxygenases and cytochrome P-450 monooxygenases
133
. Of these, the 
cyclooxygenase-prostaglandin pathway was the first to be discovered.  The cyclooxygenases 
(COX1 and COX2) are bifunctional enzymes that convert AA (and other PUFAs) to prostaglandin 
H2 (PGH2)
134
. While COX1 is constitutively expressed on most cells, COX2 is induced by several 
inflammatory mediators and is expressed in a limited number of cell types. These enzymes 
catalyze cyclooxygenation of the lipid, which is followed by a second heme-dependent 
peroxidation reaction. In these reactions, the 13-pro-S hydrogen is first stereospecifically removed 
from AA to yield a C11-C15 delocalized pentadienyl radical, which then reacts sequentially with 







Next, the 15-hydroperoxyl group of PGG2 is reduced to yield PGH2. This prostaglandin is the 
common intermediate from which all the bioactive 2-series prostaglandins are derived. Although 
is PGH2 generated in many different cell types, the further oxidation of PGH2 by specific synthases 
such as, PGE synthase, PGD synthase, PGF synthase, PGI synthase, and TXA synthase, is more cell-
type specific
133
. For example, platelets contain TXA synthase and synthesize TXA2 from PGH2 to 
stimulate vasoconstriction and platelet aggregation during hemostasis. On the other hand, 
endothelial cells express PGI synthase and biosynthesize PGI2 and renal collecting tubule cells 
contain PGE synthase and produce PGE2. Thus the formation of COX-derived products is the first 
step in prostaglandin metabolism, and these products are used by various cell-specific synthases 
to generate various prostaglandin end products.  
PUFAs are also metabolized by the lipoxygenase family of enzymes. These enzymes 
catalyze the oxygenation of PUFAs at specific unsaturated carbons and are named according to 
the position of the carbon atom oxygenated
133
. To-date, three types of lipoxygenases (LO) have 
been described in mammals: 5-LOX, 12-LOX and 15-LOX. They are expressed in leukocytes, 
platelets, reticulocytes and different types of epithelial cells. One problem with the atom-position 
designation of LOX activity is the functional overlap of oxygenation activity. For example, 15-LOX 
and 12-LOX can both catalyze the oxygenation of linoleic acid to 13-hydroperoxyoctadecadienoic 
acid. Also, soybean LOX-1 can add oxygen to both C5 and C8 of 15-
hydroxyperoxyeicosatetraenoic acid (15-HPETE)
31
. Thus lipoxygenase oxygenation site is 
substrate-dependent and not enzyme-dependent. As a result a small number of enzymes can 
generate a large variety of oxygenated PUFAs: humans encode six functional LOX genes; mice 
encode seven. Mice do not encode a reticulocyte-type 15-LOX like humans, but produce a 
leukocyte 12-LOX (termed 12/15-LOX) that shares nearly 40% sequence homology and performs 







 In humans and mice, lipoxygenases can generate both leukotriene B4 (LTB4) and lipoxin 
A4 (LXA4)31. The first step in their biosynthesis involves the oxygenation of AA at C5 to 5-HPETE, 
and then dehydration of the peroxide to from leukotriene A4 (LTA4), a highly unstable conjugated 
triene epoxide, which is an intermediate common to bothLTB4 and LXA4 synthesis.  The LTA4 is 
then converted to LTB4 by LTA4 hydrolase; whereas the conversion of LTA4 to LXA4 is catalyzed 
by 15-LOX. This divergence is highly significant during the course of inflammation because LTB4 
and LXA4 have opposing actions. LTB4 is pro-inflammatory; it is a potent neutrophil 
chemoattractant, whereas, LXA4 is anti-inflammatory and it inhibits neutrophil infiltration. During 
the early phases of inflammation, the LTB4 substrate LTA4 is predominantly shuttled through 
LTA4 hydrolase to promote inflammation. However as the timecourse of inflammation shifts to 
resolution, LTA4 is diverted to 15-LOX to simultaneously increase LXA4 synthesis and decrease 
LTB4 production. This diversion of substrate and switch in lipid mediator class is an important 
transition signal during the course of inflammation and wound healing. Furthermore, lipid 
mediators do not have be synthesized in toto in a single cell. For example, mast cells can generate 
LTA4 and release it into the blood where it is absorbed by reticulocytes and processed to LTB4
135
. 
This process of transcellular biosynthesis adds another level of lipid mediator regulation. It is 
these different levels of regulation and the large number of different AA-derived lipoxygenase 
products that contributes to the complexity of PUFA metabolism. Furthermore, DHA and EPA are 
also prominent PUFAs in animals, and they can be oxygenated by lipoxygenase enzymes. The 
same enzymes that generate LTB4 can synthesize LTB5 from EPA, which is only structurally 
different from LTB4 at the ω-3 bond position
108
. Lipoxygenases can also synthesize oxygenation 
products from DHA; however due to its extra two carbons and double bond, DHA-LOX products 
are more structurally distinct. 







from DHA55. RvD2 was first discovered in nanogram amounts during the resolution phase 
exudates of a mouse dorsal air pouch TNFα-induced inflammation model. It is a potent bioactive 
lipid mediator capable of decreasing leukocyte-endothelial interactions during inflammation, but 
also stimulate macrophage phagocytosis and endothelial NO production. In vivo, the biosynthesis 
of RvD2 first requires the generation of 17-hydroxyperoxydocosahexaenoic acid (17-HpDHA) by 
15-LOX oxygenation of C17 on DHA. The 17-HpDHA is then transformed into a 7(8)-epoxide-
containing intermediate by 5-LOX and finally enzymatically converted to RvD2. This synthetic 
process can occur in a single cell or through multiple cells. Neutrophils produce both 15-LOX and 
5-LOX and can produce RvD2 from DHA per se or from 17-HpDHA precursor by transcellular 
synthesis after interacting with other 15-LOX expressing cells. Eosinophils express high levels of 
15-LOX but not 5-LOX. The 15-LOX converts DHA to 17-HpDHA which diffuses to neutrophils that 
then produce more RvD2. There is also evidence that macrophages can produce RvD2. Mouse 
peritoneal macrophages express both 12/15 lipoxygenase and 5-lipoxygenase
136
, and 
macrophages derived from human peripheral blood monocytes can produce RvD2 in vivo
137
. 
Overall RvD2 is a novel DHA-derived lipid mediator that can be synthesized by lipoxygenases in 
leukocytes.  
In this study, we sought to determine if during revascularization, a specific cell type is 
capable of RvD2 synthesis. We verified the activity of 12/15-lipoxygenase in the hind limb after 
femoral artery occlusion, determined the leukocyte populations that are most prominent during 
revascularization, and measured their ability to synthesize RvD2. We first measured the overall 
production of lipid mediators in the muscle by targeted lipidomics analysis, and found elevated 
levels of 12/15-lipoxygenase metabolism products. We identify the different leukocyte 
populations in the ischemic hind limb by digesting the muscle tissue and analyzing the cells by 







increased during HLI.  In addition, we isolated Ly6Chi CCR2+ inflammatory monocytes from mouse 
spleen and assess their ability to synthesize RvD2 after in vitro stimulation.   Taken together, our 
data suggest that during post-ischemia revascularization the lipid mediator RvD2 was produced 
by inflammatory monocytes.  
 
Experimental procedures 
Solid phase extraction and LC/MS/MS MRM detection of lipid mediators-Pulverized limb 
muscle tissue or ionophore-stimulated monocytes were frozen in ice cold methanol at -80°C one 
day prior to solid phase extraction.  For quantification the samples were spiked with lipid 
standards (d8-5HETE, d4-PGE2, and d5-RvD2, 2ng each) to calibrate recovery during extraction. 
Butylated hydroxytoluene was added to prevent non-enzymatic oxidation. Lipid mediators were 
then purified by solid-phase extraction on a reverse phase C18 column. Methyl formate-eluted 
fractions were collected, reduced in volume by nitrogen gas evaporation and reconstituted in 
methanol. These samples were then analyzed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) using a C18 column (4.6mm x 50mm x 5.0µM) equipped high 
performance liquid chromatography system (HPLC; Shimadzu) coupled to a triple quadrupole 
mass spectrometer (API 2000; Applied Biosystems) operated in negative ionization mode.  
Samples were eluted with a mobile phase consisting of water:acetic acid (100:0.1 vol/vol) and 
acetonitrile:methanol (4:1 vol/vol) (73:27) and ramped to 30:70 over 11 min, followed by slowly 
ramping up to 20:80 over the next 10 min and held for additional 2 min. Finally, the mobile phase 
was ramped up to and held at 0:100 for 2 min, followed by a return to 73:27 for 2 min. Entire 
sample elution was performed using a constant flow rate of 300 µL/min. Unesterified free AA, 
EPA, and DHA and its endogenous metabolites were identified by multiple-reaction monitoring 







curves developed for each metabolite using purified standards (Cayman Chemical). Total 
extraction recovery and original tissue amount was calculated relative to deuterium-labelled 
internal standard and the original tissue weight or cell count.  
 
Flow cytometry of digested limbs-To identify the different individual cell populations of the 
upper hind limb, three-day post-ischemia mice were sedated with pentobarbital and 
exsanguinated by cardiac puncture. The right semitendinosus, semimembranosus and biceps 
femoris (hamstring) muscles of the upper limb were then excised, weighed, and placed in enzyme 
digestion solution consisting of 500U/mL collagenase II and 2.5U/mL dispase II in 1800µL of 
Hank’s Balanced Salt Solution. Muscles were left to digest at 37°C for 1.5 h. The digestate was 
then strained through a 40µM cell strainer and washed with 2mL of phosphate buffered saline 
with 1% bovine serum albumin (PBS-BSA). The strained cells were then stained with Fc-block 
(anti-CD16/32) and then stained with either a monocyte panel or lymphocyte panel of antibodies. 
The monocyte panel consisted of FITC anti-CCR2, PE anti-Siglec-F, APC anti-F4/80, APC/Cy7 anti-
Ly-6G, BV421 anti-CD11b, BV605 anti-Ly-6C, and PerCP anti-CD45. The lymphocyte panel 
consisted of FITC anti-αVβ3, APC anti-CD8, PE anti-CD19, Pacific Bleu anti-CD4, and PerCP anti-
CD45. After 30 min of staining, cells were washed with 1mL of PBS-BSA and then enumerated on 
a BD LSR II flow cytometer.  
 
Splenic monocyte isolation and in vitro stimulation-To obtain the splenic population of 
inflammatory monocytes, intact spleens were rapidly excised from asphyxiated mice and ruptured 
between two microscope slides. The spleen was then rubbed through a 40µM cell strainer and 
rinsed with Pharmlyse to lyse red blood cells. After a 5 min incubation in the dark at room 







EDTA and 0.5% bovine serum albumin (MACS buffer). A Mouse Monocyte Enrichment Kit from 
Stemcell Technologies was then used to deplete the non-monocyte populations by antibody-
biotin-magnetic bead separation. The remaining non-depleted population was confirmed by flow 




 monocytes. In 12/15-lipoxygenase 
knockout mice, additional biotin-conjugated ant-F4/80 antibody was added to the enrichment 
procedure to deplete an extra population of macrophages. After isolation of splenic monocytes, 
cells were washed with Hank’s Balanced Salt Solution to remove EDTA and supplement calcium. 
Monocytes were then divided and stimulated with 10µM of A23187 calcium ionophore and 10µM 
docosahexaenoic acid for 30 min at 37°C. The stimulation was then halted with 1.5mL of ice cold 
methanol and the entire solution was frozen at -80°C for LC-MS/MS analysis.  
 
Results 
12/15 lipoxygenase is active during revascularization-12/15-Lipoxygenase (12/15-LOX) is a 
lipid-peroxidating enzyme expressed in reticulocytes, eosinophils, airway epithelial cells, 
monocytes and macrophages. It is also the first biosynthetic enzyme in RvD2 production and it 
converts DHA into 17-HpDHA (Figure 5A). Therefore 12/15-LOX must be expressed and active to 
generate RvD2 during post-ischemia revascularization. Therefore to determine 12/15-LOX in the 
post-ischemic limb, we harvested mouse ischemic limb tissue three days after right femoral artery 
and vein ligation. The tissue was pulverized, unesterified lipids were extracted by solid phase 
extraction, and the various lipid mediators were identified by LC-MS/MS (Figure 5B).  This analysis 
led to the identification of the well-described inflammatory mediators LTB4, PGE2 and PGD2. 
Detectable levels of these lipids confirms that our procedure for inducing hind limb ischemia 
caused tissue damage and elicited a reparative response involving inflammation. We also found 







biosynthetic pathway. More importantly, we detected the 12/15-LOX metabolites 12-HETE, 15-
HETE, 12-HEPE, 15-HEPE, 14-HDHA, and 17-HDHA in extracted muscle tissue, indicating the 
presence of 12/15-LOX activity.  The amount of 12/15-LOX products was several fold higher than 
5-LOX products, suggesting the overall activity of 12/15-LOX is higher than 5-LOX. Furthermore, 
because the HETEs are metabolites of AA, the HEPEs are metabolites of EPA, and the HDHAs are 
metabolites of DHA, their simultaneous presence implies that cells involved in revascularization 
are utilizing all three predominant PUFA substrates (AA, EPA, DHA). Interestingly, the production 
of DHA metabolites was several-fold higher than their EPA and AA counterparts. Overall, these 
results suggest hind limb ischemia elicits the production of established inflammatory lipid 











 inflammatory monocytes (referred herein as inflammatory monocytes) are critical to the 
revascularization process. Therefore, we analyzed mouse hind limbs to determine if these cells are 
recruited in our revascularization model.  For this, we digested limb tissue from sham control and 
femoral-ligated animals with collagenases, fluorescently labelled the liberated cells with a panel of 
leukocyte marker antibodies, and measured cell numbers by flow cytometry. We isolated tissue 
three days after ligation surgery to correspond with our previous lipidomics data. In this three-day 





 neutrophils (Figure 6). There was no increase in the percentage of 
CD19
+
 B-cells, CD4 T-cells, CD8 T-cells, Siglec-F
+
 eosinophils or Ly-6C
lo
 resident monocytes (data 
not shown). This data are consistent with other investigations of hind limb ischemia and suggests 








Isolated inflammatory monocytes are capable of producing RvD2-We next sought direct 
evidence of RvD2 production by inflammatory monocytes after confirming their infiltration during 
revascularization. While previous reports have demonstrated the expression of 12/15-LOX in both 
monocytes and macrophages
138
, we chose to seek direct evidence for RvD2-synthesis by 
inflammatory monocytes because it is possible to isolate a pure population of these cells from the 
splenic reservoir. Using magnetic bead negative selection separation, we depleted all other 
leukocyte populations from isolated mouse spleens to collect only inflammatory monocytes 
(Figure 7B).  Then, we incubated these monocytes with DHA substrate and simultaneously 
activated the cells with A23187 calcium ionophore for 30 min. DHA-derived products were then 
extracted and identified by LC-MS/MS.  We found that RvD2, RvD1, 14-HDHA, 17-HDHA, and 
10,17-diHDHA, were all biosynthesized in large quantities (Figure 7C). To confirm that these lipids 
were produced by 12/15-LOX-metabolized precursors, we isolated the same population of 
inflammatory monocytes from mice missing the 12/15-LOX gene and repeated our in vitro 
stimulation and LC-MS/MS analysis. Our results showed that the RvD2, RvD1, 14-HDHA, 17-
HDHA, and 10,17-diHDHA production was either completely abolished or dramatically decreased. 







Figure 5: 12/15-lipoxygenase biosynthesis products during revascularization. (A) 12/15- 
lipoxygenase and 5-lipoxgenase oxygenate PUFAs at different carbon positions to yield different 
metabolites. (B) PUFA metabolites extracted from the hamstring muscles of ischemic limbs three 
days after occlusion. LC-MS/MS quantitated amounts were normalized to the weight of the 

























































































Figure 6: Leukocyte populations during revascularization. (A) Leukocyte population changes in the 
hamstring muscles during revascularization three days after induction of hind limb ischemia. The 
two axes used to gate populations are labelled on the Y-axis. Y-values are expressed as the 
percent of a population gate from the total count population. n=5 per group, * indicates p<0.05. 





















































































































































Figure 7: Ly-6Chi, CCR2+ inflammatory monocytes produce RvD2. (A) Biosynthetic scheme of RvD1 
and RvD2 from DHA substrate and 17-HpDHA intermediate by 12/15-LOX and 5-LOX enzymes. 
(B) Representative images of mouse spleen purification by magnetic bead negative selection 
separation to yield highly enriched population of Ly-6Chi, CCR2+ inflammatory monocytes. (C) 
Production of 12/15-LOX metabolites by splenic inflammatory monocytes from wildtype or 





















































































The major finding of this study is that revascularization-elicited Ly-6Chi, CCR2+ 
inflammatory monocytes express 12/15-LOX and have the capacity to synthesize RvD2. We found 
the presence of 12/15-LOX and 5-LOX biosynthetic activity in mouse hind limbs three days after 
induction of ischemia, and an increase in inflammatory monocytes in the tissue at this same time. 
We then isolated this inflammatory monocyte population and stimulated them in vitro to 
demonstrate direct RvD2 production. Finally, we authenticated the 12/15-LOX origin of this RvD2 
by ablating 12/15-LOX, which obliterated RvD2 synthesis. Overall, these results support the notion 
that infiltrating monocytes generate pro-resolving lipid mediators during post-ischemic 
revascularization.  
Our 12/15-LOX and monocyte results are consistent with the conclusions of other 
investigations. Other studies show that 12/15-LOX is important in the revascularization process
92
, 
and that the enzyme is expressed in monocytes and macrophages
139
. Previous studies suggest 
that 12/15-lipoxygenase is important during revascularization because ablation of this enzyme 
hinders the ability of mice to recover blood perfusion in the hind limb ischemia model. However, 
this observation does not correspond directly to enzyme activity as the investigators did not 
measure 12/15-LOX enzyme products in vivo during revascularization. Thus we began our inquiry 
by examining 12/15-LOX activity during post-ischemia revascularization by identifying known 
12/15-LOX lipid metabolites directly in mouse limbs. Because 12/15-LOX can be expressed in 
many different cell types, it was important that we attribute our observed 12/15-LOX activity 
specifically to monocytes and macrophages. The expression of 12/15-LOX in different monocyte 
and macrophage populations has been corroborated by many studies. Most germane to our 
investigation is not just the presence of 12/15-LOX mRNA or protein in monocytes and 







question by in vitro stimulation of spleen-isolated inflammatory monocytes to obtain 12/15-LOX 
products, including RvD2. Then, we further validated this enzyme-cell specificity by ablating 
12/15-LOX and demonstrating the absence of previously detected enzyme products. This allowed 
us to confirm that inflammatory monocytes can produce RvD2.  
Several studies suggest that monocytes and macrophages are critical to the 
revascularization process, and that inflammatory macrophages increase at injury sites during the 
early phases of repair. Monocytes and macrophages are critical to the revascularization process 
because in several specific knockout models depletion of these cells or inhibition of their normal 
functions attenuates post-ischemic recovery
140
. For example, granulocyte-colony stimulating 
factor deficient mice, which cannot differentiate monoblasts into mature blood monocytes or 
tissue macrophages, have significantly impaired revascularization ability
141
. Depleting monocytes 
and macrophages by 5-fluorouracil or a diphtheria-toxin-CD11b-gene suicide-triggering system 
also decreases perfusion recovery after ischemia
142
. Mice that cannot produce CCL2, the potent 
monocyte and macrophage chemoattractant, also have revascularization deficits
143
. The increase 
in monocyte and macrophage percentages in day-three post-ischemic limbs thus corroborates 
previous findings. Moreover, our observation of increased inflammatory monocytes but 




) specifically mirrored reports that there are two 
populations of peripheral blood that are present during different time points of inflammation. 
Inflammatory monocytes are rapidly recruited to sites of injury within hours, while resident 
monocytes appear many days later
45
. There is also evidence that resident monocytes at 
inflammatory sites are not new infiltrates; they are simply phenotype-switched original 
inflammatory monocytes
144
. Nevertheless, the spleen is a reservoir of both monocyte 
phenotypes
45
. We not only measured an increase of inflammatory monocytes (and no change in 







mouse spleens and confirmed their specific Ly-6Chi, CCR2+ phenotype.  
We are cognizant of the fact that inflammatory monocytes represent the largest 
proportion of leukocytes digested from limb muscles (20%, Figure 6A). All the reported leukocyte 
percentages were gated on the total cell count; therefore the reported percentages are on an 
absolute scale. Additionally, inflammatory monocytes were not the only cell type increased as 
there was also an increase in the percentages of F4/80
+
 macrophages and Ly-6G
+
 neutrophils. 
Nevertheless, we did not isolate and stimulate macrophages because F4/80 is a pan-macrophage 
surface marker that does not differentiate among the various macrophage phenotypes. Thus we 
were not confident in our ability to isolate a population of macrophages for in vitro stimulation 
that directly corresponded to cells that were increased during revascularization. Additionally, we 
did not isolate and stimulate neutrophils because we counted very few of them in digested 
muscle limbs and others studies have reported that although neutrophils express 12/15-LOX, the 
enzyme has little activity until the cell is robustly stimulated
145
. Since neutrophils can have many 
states of differentiation and activation once they are mobilized from the bone marrow, we also 
did not isolate them for stimulation
11
.  
There are other cell types that are increased during the revascularization process that we 
did not enumerate. Previous work has shown that B-cells and T-cells can also influence the 
revascularization process but again we did not observe any changes
146
. Various progenitor cells, 
fibroblasts, and vascular smooth muscle cells can all increase in post-ischemia limb tissue; 
however, we did not measure them
147, 148
. The main reason is we only examined a single early time 
point during the revascularization process. Lymphocytes and mesenchymal cells appear 
predominantly later when the tissue is regenerating.  Since our initial observations at day three 
post-occlusion were consistent with other reports, and the 12/15-LOX activity in these other cell 







timecourse. In the future, a more comprehensive timecourse study of 12/15-LOX activity and cell 
infiltration after hind limb ischemia would be needed to account fully for the various cell types 
than can produce RvD2 in post-ischemic tissue.  
The appearance of EPA and DHA products in ischemic limb samples is consistent with 
observations that systemically available unesterified EPA and DHA can be shuttled to active sites 
of inflammation to act as a precursor of lipid mediators
149
. While humans cannot desaturate EPA 
and DHA natively and must derive it from their diet, EPA comprises 0.5-2.8% of total body fatty 
acids and DHA comprises approximately 0.3-5.0%
149
. Mice do not possess PUFA desaturases 
either, but their diet contains EPA and DHA
133
. We also found metabolites of EPA and DHA in our 
pulverized ischemic limb samples. There were two noteworthy results in our data. One, tissue 
levels of 14-HDHA and 17-HDHA were significantly higher than EPA and AA 12/15-LOX products. 
Two, we were not able to detect resolvins in our limb samples. The availability of DHA at the 
revascularization site could be higher than EPA and AA, because there are many different 
phospholipase A2s and other classes of phospholipases, the actual liberation of DHA, EPA and AA 
free esters can be subject to complex regulatory mechanisms
131
. In specific contexts, there can be 
a preferential liberation of one PUFA over another. Secondly, our failure to detect RvD2 directly in 
post-ischemia limb tissue must be addressed. Normal murine resolution-phase peritoneal 
exudates contain only nanograms of RvD2 and supplementation of free DHA to the resolution site 
to drive substrate flux through the RvD2 biosynthetic pathway can boost synthesis, but the 
amount in muscle tissue is either less concentrated or harder to extract
55
. Therefore, a detection-
limit problem may have plagued our analysis of ischemic limb. In addition, like many other 
bioactive lipid mediators, RvD2 can be rapidly inactivated by dehydrogenases into degradation 
products that were not identified by our current protocol. Furthermore, we only examined only 







samples suggest the nadir of post-ischemia inflammation may have already passed, the peak of 
the resolution, during which RvD2 is abundantly generated, may be yet to occur. Finally, our 
rationale for studying the role of RvD2 in revascularization was based on the dual 
immunovascular effects of this mediator and not because it is most abundant during 
inflammation, resolution or revascularization. Therefore a more comprehensive assessment of the 
timecourse of lipid mediator metabolism during revascularization is needed to understand the 
dynamics of RvD2 biosynthesis and the generation of other more endogenously preferred lipid 
mediators.  
Finally, a few questions about RvD2 biosynthesis remain unanswered. The enzymatic 
conversion of the 7,8-epoxide intermediate into either RvD1 or RvD2 is not well described
55
. Are 
there one or two enzymes, and how is the production of RvD1 versus RvD2 regulated? We have 
also focused on 12/15-LOX in this study, but 5-LOX is also important in the biosynthesis of RvD2 
(the second step). From our limb samples, it appeared that 5-LOX products, including RvD2, were 
not generated as abundantly as 12/15-LOX products;. Whether this lack of production was the 
result of enzyme regulation or substrate diversion needs to be elucidated. The 5-LOX is the rate-
limiting enzyme in leukotriene synthesis, and perhaps as a result it also limits RvD2 synthesis
31
. 
Once again, the time period at which we measured 5-LOX metabolites may not coincide with its 
maximal enzymatic activity.  
In conclusion, we have documented the specific RvD2-generating 12/15-lipoxygenase 
activity in ischemic injury-recruited Ly-6Chi CCR2+ inflammatory monocytes in this study. 
However, we did not directly detect RvD2 in the injured tissue of mice subjected to hind-limb 
ischemia. In the future, we plan to improve our analysis by performing a comprehensive temporal 












MECHANISMS OF REVASCULARIZATION ENHANCEMENT BY RESOLVIN D2 
Introduction 
 Arteriogenesis and angiogenesis are the two processes by which new vasculature is 
formed in adult animals
150
. Arteriogenesis is the development process of preexisting collateral 
arterioles into arteries to circumvent an occlusion in a large artery, whereas angiogenesis is the 
growth of new capillaries by sprouting and intussusception of preexisting capillaries to perfuse 
areas of tissue hypoxia. Both processes are critical to revascularization and the restoration of 
blood perfusion in the ischemic tissue. Timely and robust revascularization is essential to stem 
tissue damage, such as in cases of myocardial infarction, ischemic stroke and critical limb 
ischemia. In our previous studies, we have demonstrated that the pro-resolving lipid mediator - 
Resolvin D2 (RvD2) can enhance revascularization in a mouse model of critical limb ischemia. 
RvD2-treated animals have increased vascular volume in their ischemic limb and display reduced 
histologic signs of muscle damage. In addition, several other investigators have defined a clear 
role for monocytes and macrophages in the normal revascularization process, and they have 
demonstrated that transfusion of additional monocytes and macrophages can enhance 
revascularization
72




 inflammatory monocytes, which 
are highly present during limb revascularization, have the endogenous ability to synthesize RvD2, 
but the mechanism by which RvD2 enhances revascularization remains unclear. Previous work has 
shown that revascularization is mediated primarily by three cell types: monocytes and 
macrophages, vascular smooth muscle cells, and endothelial cells
73







all these cell types during revascularization.  
 Monocytes and macrophages can synthesize RvD2, and they can be stimulated by RvD2 
in a paracrine or autocrine manner
137
. RvD2 is synthesized from docosahexaenoic acid (DHA) by 
12/15-lipoxygenase and 5-lipoxygenase
55
. Monocytes and macrophages express both enzymes, 
and our studies from our laboratories and those of others have demonstrated that in vitro, these 
cells can synthesize RvD2. Once synthesized, RvD2 can in turn stimulate monocytes and 
macrophages. In a mouse zymosan-induced peritonitis model, intravenous injection of 100ng of 
RvD2 prior to zymosan-stimulus resulted in greater monocyte infiltration into the peritoneum. 
Isolated mouse peritoneal macrophages also are stimulated by RvD2 to ingest FITC-labelled 
zymosan particles in an in vitro phagocytosis assay. Thus RvD2 can be biosynthesized by 
monocytes and macrophages, and it can also directly stimulate them. Nevertheless, other cell 
types can be affected by RvD2 as well.  
 Vascular smooth muscle cells (VSMC) are another target of RvD2. A recent investigation 
provides detailed insights into its stimulatory actions in VSMC
151
. In vitro, RvD2 attenuates the 
proliferation of VSMC in basal culture conditions, and in migration chambers RvD2 decreased 
VSMC chemotaxis toward a PDGF gradient. RvD2 also decreases TNFα-stimulated expression of 
VCAM-1, ICAM-1, IL-1β, IL-6, and CCL2 mRNA in VSMC. In vivo, RvD2 decreased rates of cell 
proliferation, as measured by Ki-67 staining, in the vessel wall of balloon catheter-injured rabbit 
femoral arteries. In histologic sections of these arteries, neointimal hyperplasia was found to be 
decreased. These data are consistent with the in vitro results showing the anti-proliferative effects 
of RvD2.  In addition, RvD2 can also decrease ROS production as indexed by dihydroethidium 
staining, leukocyte infiltration, and inflammatory cytokine production (TNFa, IL-1, CCL2) in femoral 
arteries. Collectively, these data provide evidence, which suggests that RvD2 elicits an inhibitory 







 RvD2 can also stimulate endothelial cells55. In mouse ears, topical application of 100pg of 
RvD2 dilates the ear microvasculature as quantitated by increased FITC-albumin signal. 
Interestingly, application of a nitric oxide inhibitor (L-NAME) abolished this dilatory effect, 
suggesting a potential nitric oxide-dependent mechanism. In the mouse cremaster 
microcirculation model, RvD2 administration was found to decrease platelet activating factor-
stimulated neutrophil adhesion to the endothelium. This observationhas been replicated in vitro 
in a flow chamber, and it was found that RvD2 decreased PAF-stimulated capture and adhesion of 
neutrophils by human umbilical vein endothelial cells (HUVEC). Additionally, RvD2 directly 
stimulates HUVECs to produce more prostacyclin and nitric oxide, two highly potent vasoactive 
mediators. In a separate investigation, the vasoactivity of RvD2 was found to prevent secondary 
thrombosis of deep dermal vascular network after burn injury to aid in the preservation of 
microvasculature
152
. Together, this body of evidence indicates that in addition to its established 
immunomodulatory actions, RvD2 has potent vascular effects.  
 RvD2 can enhance revascularization and affect the three predominant cell types involved 
in the revascularization process, but significant mechanistic questions remain unanswered.  
Specifically, it remains to be clarified whether RvD2 can directly stimulate arteriogenic and 
angiogenic gene expression in these cells, or whether RvD2 affects endothelial proliferation and 
migration. Results of our present study provide evidence that RvD2 does not stimulate 
arteriogenic, angiogenic, or inflammatory gene expression in isolated macrophages or endothelial 
cells.  Our results also show that RvD2 does not stimulate angiogenesis in an in vivo Matrigel plug 
assay, and it does not enhance endothelial cell proliferation. However, we found that RvD2 
stimulates endothelial migration in a Rac-1 dependent manner. As endothelial migration is 
important for mechanotaxis during the changes in shear stress experienced after arterial occlusion 







RvD2 enhances arteriogenesis, but not angiogenesis by stimulating endothelial migration.  
 
Experimental procedures 
Multiplex ELISA analysis of mouse plasma-Mouse peripheral blood was collected by cardiac 
puncture, anti-coagulated with 16 µL of 200mM EDTA, and centrifuged at 2000 xg for 20 min. The 
plasma supernatant was collected and frozen at -80°C. Multiplex ELISA analyses were then 
performed by Quansys Biosciences.  
 
Realtime reverse transcriptase polymerase chain reaction- Mouse hamstring and 
gastrocnemius were harvested, snap-frozen in liquid nitrogen, and powdered with a tissue 
pulverizer. The tissue powder was incubated and vortexed in TRIzol (Life Technologies) for 5 min. 
Afterwards, samples were incubated with chloroform for 3 min and then vortexed at 12,000 x g for 
15 minat 4°C. The upper aqueous phase was then transferred to a new tube and mixed with 1 
volume of 70% ethanol. Isolated peritoneal macrophages and Mile Sven 1 (MS1) endothelial cells 
were scraped with a cell scraper and lysed with Buffer RLT (Qiagen). Total RNA solutions from 
either mouse tissue, or cell lysate in Buffer RLT, were then purified with an RNeasy kit (Qiagen). 
RNA quality was checked by 260/280 UV absorbance ratio with a Nanodrop (Thermo). cDNA was 
prepared by polymerase chain reaction using avian myeloblastosis virus reverse transcriptase and 
oligoDT primers. The PCR cycling parameters were one cycle of 95°C for 10 min, then 40 cycles of 
15 s at 95°C and 60 s at 60°C. 
The cDNA was then analyzed by real-time PCR by the SYBR green and ΔΔCt method to 
quantitate the reverse-transcribed messenger RNA. The cDNA samples were mixed in duplicate 
with specific RT-PCR forward and reverse primers (SA Bioscences or IDT DNA) and PerfeCTa SYBR 







(HPRT) housekeeping gene was used as internal quantitation control. Samples were then 
measured with a Prism 7900 HT (Applied Biosystems). The realtime cycling parameters were one 5 
min cycle at 95°C, then 45 cycles of 10 s at 95°C, 20 s at 60°C, and 25 s at 72°C. SYBR green 
fluorescence from amplified cDNA was recorded at the end of each cycle and the number of 
cycles at which a sample crossed the threshold value was noted. Quantitation of mRNA 
expression was then performed using the 2
−ΔΔCt
 mathematical model, where ΔΔCt = ΔCtgene of 
interest − ΔCthprt. 
 
Matrigel plug assay-Matrigel is an extracellular matrix mixture secreted by Engelbreth-Holm-
Swarm mouse sarcoma cells
153
.  A 500µL aliquot of Matrigel (Cultrex HC, Trevigen) was thawed on 
ice and mixed with either no additives, 500ng FGF2 + 50U heparin, 100ng RvD1, or 100ng RvD2. 
The mixture was then loaded into syringes with attached 25 gauge needle. The mouse was then 
anesthetized with isoflurane and denuded with depilatory cream on the right lateral abdomen.  
The Matrigel mixture was then injected subcutaneously under the skin and allowed to solidify into 
plugs for 20 min. The mouse was then allowed to awaken and recover for seven days. On the 
seventh day, the mouse was euthanized and the Matrigel plug was excised. To release the 
infiltrated endothelial cells, the Matrigel plugs were digested with 5mg/mL of Type I and II 
collagenase in 1mL of Hank’s Balanced Salt Solution for 1 hour at 37°C. Afterward, digested plugs 
were strained with a 40µM cell strainer and rinsed with PBS-BSA. The cell solution was then 
stained with Fc-block (anti-CD16/32) and FITC anti-CD45, PE anti-CD31, PE/Cy7 anti-CD105, and 
APC anti-CD144. After a final rinse, cells were analyzed on an Accuri flow cytometer.  
 
Scratch migration assay-MS1 cells were seeded at one millions cells per 6cm cell culture well the 







200µL pipette tip, two vertical scratches were made across the culture dish. The scratch was then 
imaged and the medium was replaced with fresh media plus stimuli. Eighteen hours later, the 
plates were imaged again and discarded. The 0 h and 18 himages were then processed by 
Photoshop (Adobe) with vertical lines demarcating migration of cells into the scratch site, and 
then analyzed for migrated width using Image J (NIH).  
 
MTT & EdU proliferation assay-MS1 cells were seeded at 10,000 cells per 96-well well in 100µL 
of 1% serum DMEM overnight. The next morning, cells were given new media with various stimuli 
and incubated at 37°C for 48 h.  Cell proliferation was measured using an MTT assay kit 
(Invitrogen) or EdU kit (Molecular Probes) and quantitated on a microplate reader (Biotek).  
 
Rac1 pulldown assay-MS1 cells were cultured on 150mm plates in 30mL of DMEM with 10% FBS 
until half confluent. Culture media was then changed to 1% serum DMEM for 18 hours. Cells were 
then stimulated with 1nM RvD2 or unstimulated and VEGF controls for 30 m. Plates were then 
rinsed with cold PBS to halt the reaction. Cells were then lysed and phosphorylated Rac1 was 
precipitated with a Rac1 activation kit from CellBiolabs.  
 
Western blotting-Rac1 pulldown samples were separated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) 
membranes. The membrane was blocked overnight in tris-buffered saline with 1% tween20 (TBS-
T) and 5% powdered milk. Precipitated Rac1 and total Rac1 was then probed with anti-Rac1 (Cell 
Signaling Technologies) and anti-rabbit-HRP in TBS-T with 1% BSA. Membranes were then 
developed with HRP substrate (Millipore) and scanned with a Typhoon bioimager (GE Healthcare). 









Leukocyte numbers in ischemic hamstring muscles are not significantly altered by RvD2 
treatment-In our previous study, we demonstrated that our hind limb ischemia model elicited an 
increase in certain myeloid cells and did not alter other leukocytes three days after occlusion. We 
then asked if RvD2 can alter any of these leukocyte populations.  To address this question, we 
digested ischemic semitendinosus, semimembranosus and biceps femoris (hamstring) muscles, 3 
days post-occlusion, and enumerated leukocytes as a percentage of total counts.  We found that 
there was no statistically significant difference in neutrophil and macrophage percentages in 










monocytes, B-cells and CD4 T-cells. Overall, RvD2 treatment during revascularization did not alter 
leukocyte populations in the ischemic muscle compared with vehicle treatment on day 3 after 
occlusion.  
 
Plasma cytokine changes three days after HLI-The systemic plasma levels of cytokines can 
change after local ischemia.  Therefore, we measured a panel of cytokines that are often increased 
during revascularization (Figure 9). Changes in fluid shear stress can stimulate endothelial cells to 
release CCL2. We did not detect a statistically significant increase in CCL2 after HLI. There was a 
strong upward trend however, suggesting simply a lack of statistical power. Regardless, there was 
no change in CCL2 with RvD2 treatment either. Consistent with other studies, RvD2-treated HLI 
mice possessed lower circulating TNFα, a major inflammatory cytokine, compared with vehicle-
treated mice. There was a similar decrease in GM-CSF with RvD2 treatment, too. Conversely, IL-4 







control groups (sham treatments, and vehicle-HLI), and was present only in RvD2-treated mice. 
Collectively, these results indicate that RvD2 can alter systemic levels of important cytokines that 
mediate revascularization.   
 
mRNA expression changes in ischemic hamstring muscles three days after HLI-Hind limb 
ischemia can also alter the expression of revascularization-mediating genes. To measure these 
genes, we isolated total RNA from vehicle or RvD2-treated ischemic hamstring muscles three days 
after surgery, and measured mRNA expression of a panel of arteriogenic and angiogenic genes. 
When normalized to vehicle-treated sham hamstrings, we did not observe statistically significant 
changes, by multiple comparisons (T-tests), in Vegfa, Vegfr2, Tnfa, Tie2, Vcam, Ccl2, Arg1, Il1b, 
Emr1, and Il6 (Figure 10A). However, although our sample size was small and lacked statistical 
power, there were some encouraging trends. Subsequent analysis comparing RvD2-treated 
samples only with vehicle-treated samples resulted in a statistically significant increase in Vegfa, 
Tie2, Arg1 (Figure 10B). The fold changes in the genes were modest however, and taken together 
the RT-PCR data suggest that RvD2 does not significantly affect gene transcription in ischemic 
limb during revascularization.  
 
mRNA expression changes in RvD2-stimulated peritoneal macrophages-We also measured 
direct modulation of gene transcription in macrophages by RvD2.  For this, we isolated peritoneal 
macrophages from wild-type mice and stimulated cells in vitro for 4 h with 0.1nM RvD2. We 
measured the mRNA of the three genes elevated in the muscle samples, Vegfa, Tie2 and Arg1, but 
did not find any changes (Figure 10B). There were also no changes in Ccl2, Tnfa, Il1b, Il6, Il10, 
Mmp2, Pdgfa, Nos2, Cxcl12, Ptgs2, Alox5, or Alox 15. We did measure an increase in Mmp14 mRNA 







involved in the activation of other metalloproteinases during matrix remodeling. With the 
exception of Mmp14, RvD2 did not robustly stimulate gene transcription in macrophages.  
 
RvD2 stimulates endothelial migration but not proliferation-Endothelial cells are critical 
participants in revascularization. They perform two essential activities, i.e., migration and 
proliferation
71
. We thus examined if RvD2 affects either of these two activities.  Using MS1 mouse 
microvascular endothelial cells, we performed in vitro scratch assays with different doses of RvD2 
and found that the rate of scratch wound closure was enhanced (Figure 12A). We also performed 
cell proliferation assays employing 5-ethynyl-2'-deoxyuridine (EdU) incorporation, Hoescht 
nuclear dye or MTT tetrazole as markers of proliferation. In the EdU assay, RvD2 did not stimulate 
an increase in EdU incorporation. In the Hoescht and MTT assays, we did not find any RvD2-
stimulated increase in MS1 cell number (Figure 12B). These data suggest that RvD2 can enhance 
endothelial migration but not proliferation.  
 
RvD2 does not stimulate angiogenic gene expression changes in endothelial cells-Because 
RvD2 can directly stimulate endothelial cells, we also asked if any genes were simultaneously 
transcribed. After stimulating MS1 cells for 4 h, total RNA was isolated and mRNA was quantitated 
by RT-PCR. There was no difference in Vegf1, Tie2, Ccl2, and Mmp14 (Figure 13A). Thus we did not 
uncover any RvD2-stimulated gene transcription in endothelial cells.  
 
RvD2 does not stimulate angiogenesis-The in vivo Matrigel plug assay is a simple but effective 
method to assay angiogenic effects of study compounds
153
. Many investigators harvest the 
Matrigel plug one week after implantation and perform histologic analysis. We chose instead to 







collagenase-digested plugs. Matrigel plugs containing no compounds (negative control), basic 
fibroblast growth factor (bFGF, 500ng, positive control) or RvD2 (100ng) were implanted and 
harvested after 7 days. bFGF stimulated a robust infiltration of endothelial cells, giving the excised 
plug a red appearance and firm texture (Figure 13B). RvD2-infused plugs were no different from 
negative control plugs; they retained no red color, disintegrated during tissue excision, and 
contained few endothelial cells. The results of this assay suggest that RvD2 does not stimulate 
angiogenesis.  
 
RvD2 stimulates migration through eNOS and Rac1-Endothelial migration can be stimulated 
by many pathways
154
. To gain further insights into which pathways RvD2 stimulates in endothelial 
cells, we performed scratch assays with inhibitors to two important mediators of migration: L-NG-
nitroarginine methyl ester to inhibit endothelial nitric oxide synthase (eNOS); NSC23766 to inhibit 
Rac1. Both compounds ablated the stimulatory effect of RvD2 on MS1 migration (Figure 14A). To 
provide further evidence of Rac1 pathway involvement, we used a Rac1 activation assay to 
measure RvD2-stimulated GTP binding to Rac1. The activation assay is a bead precipitation 
procedure using the PAK protein binding domain to capture only GTP-bound (ie. active) Rac1. 
Precipitated Rac1 is then normalized with total cellular Rac1 by immunoblot and quantitated by 
densitometry. RvD2 stimulation of MS1 cells increased the proportion of active GTP-bound Rac1 
to total Rac1 (Figure 14B).  Results from the scratch assay and activation assay suggest that RvD2 








Figure 8: Leukocytes numbers in ischemic muscles are not altered by RvD2. Hamstring muscles 
from the ischemic limb of mice, treated with saline vehicle or RvD2 for 3 d after induction of HLI, 
were excised and digested by collagenases to liberate individual cells. Populations of leukocytes 
were identified by a panel of indicated surface markers and enumerated by flow cytometry. (A) 
Representative contour plots of neutrophil vs macrophage flow cytometry and quantitated graphs 
of all experiment groups. (B) Quantitation of other leukocyte populations in digested ischemic 



































































































































































































































































































Figure 9: Plasma cytokine changes three days after HLI. TNFα, IL-4, IL-10 and GM-CSF cytokine 















































































































































Figure 10: mRNA expression changes in hamstring muscles 3 d after HLI. (A) Quantitation of 
mRNA in 3 d HLI ischemic hamstring muscles. Relative expression was calculated by comparing to 
average Hprt expression in vehicle-treated sham surgery samples. (A) Same samples but with 
relative expression calculated by comparing to average Hprt expression in vehicle-treated HLI 















































































Figure 11: mRNA changes in RvD2-stimulated peritoneal macrophages. RT-PCR of isolated mouse 



























































































































































Figure 12: RvD2 stimulates endothelial migration but not proliferation. (A) RvD2 stimulates MS1 
endothelial cell migration in a dose dependent manner. Representative scratch assay pictures 
indicate extent of migration. n= 6, *p<0.05 (B) RvD2 does not stimulate MS1 endothelial cell 
















































































































Figure 13: RvD2 does not stimulate angiogenesis. (A) RT-PCR of MS1 endothelial cells stimulated 
with 10nM of RvD1 for 4 hours. n= 3, *p<0.05 (B) Representative photos of excised Matrigel plugs 


















































































































































Figure 14: RvD2 stimulates migration through eNOS and Rac1. (A) Inhibition of MS1 endothelial 
migration by eNOS inhibitor L-NAME and Rac1 inhibitor NSC23766 in scratch assays. n= 6, 
*p<0.05 (B) Representative blots of Rac1 activation assay. MS1 endothelial cells were stimulated 









































































































The major findings of this study are that: RvD2 treatment modulates peripheral blood 
cytokine levels but not muscle leukocyte populations 3 days after HLI induction; RvD2 stimulates 
modest gene transcription in 3-day ischemic muscle but not gene transcription in isolated 
macrophages and endothelial cells; and RvD2 stimulates endothelial migration but not 
proliferation or angiogenesis. Taken together with our previous study demonstrating 
revascularization enhancement (Chapter 2), we conclude that RvD2 promotes revascularization by 
stimulating endothelial migration to enhance arteriogenesis, but not by stimulating angiogenesis.  
 RvD2 enhances arteriogenesis because it stimulated a robust increase in limb perfusion 
within the first week after femoral artery and vein occlusion. In our LDPI data, RvD2-treated mice 
showed increased ischemic limb perfusion. This increase was 475% from 8% of the non-ischemic 
limb to 46% by day 7, but in vehicle-treated mice perfusion was increased only by 150% from 8% 
of the non-ischemic limb to 20%. Between day 7 and 14, RvD2-treated mice gained a further 40% 
increase in perfusion, while the gain in vehicle-treated mice was 48%. Therefore the rate of 
recovery in the second week was very similar compared with the rate of recovery in the first week. 
This recovery differential is corroborated with our Microfil-microCT data. In the 3-day mild-HLI 
Microfil-microCT data, the vascular volume differential between RvD2 and vehicle treatments was 
23%. In the 7-day severe-HLI data, the vascular volume differential was only 11%. The potential 
acute role for RvD2 during revascularization has cascading effects on many of our subsequent 
cellular and molecular analyses. A robust arteriogenic response can effectively restore perfusion, 
reduce hypoxic stimulus, and dispense with a robust angiogenic response
75
. This is highlighted in 
the Microfil-microCT pictures. Despite an obvious focal interruption of blood flow, the immediate 
downstream femoral artery and vein sections are still perfused with Microfil. Clearly, collateral 







recovery predominates immediately after occlusion, and our physiologic evidence supported an 
acute role for RvD2 during revascularization, we focused our subsequent analyses on mechanisms 
within the first week after HLI.  
 The 3 day post-HLI muscle cell population and muscle mRNA expression data do not 
show major changes. RvD2, and other resolvins, robustly decrease neutrophil infiltration in many 
inflammation models
114
. Although we found a trend towards a decrease in neutrophils with RvD2, 
the data was not statistically significant. This is most likely due to a lack of statistical power or 
measurement at a suboptimal time. Other leukocytes, including monocytes and macrophages, did 
not change either. However, unchanged cell numbers do not preclude stimulation of acute 
actions. We also interrogated gene expression in both the hamstring muscles and the 
gastrocnemius. We did not find any differences in the gastrocnemius (data not shown) and only 
modest changes in Vegf, Tnfa, Tie2 and Arg1. However, these gene transcription experiments were 
performed with the tissue, which contains a heterogenous mixture of cells. Differential gene 
transcription changes in different cells could potentially mute overall transcription changes. Also, 
mRNA expression changes may not directly correlate with acute physiologic and cellular actions; 
VEGF can be produced a priori and stored in ECM-bound granules
155
. These limitations prompted 
us to interrogate systemic soluble mediator changes and isolated cell stimulation.  
 To assess RvD2 and revascularization-induced changes in realtime, we also analyzed 3 d 
plasma with a multiplex ELISA of cytokines and chemokines. At this time, we found that there was 
a decrease to baseline in TNF-α levels and an increase above detection in IL-10 levels. These 
observations are consistent with the forward shifting of the inflammation and revascularization 
timecourse
43
. TNFα is the prototypical inflammation-phase cytokine, and IL-10 is a hallmark 
resolution-phase cytokine
14
. Inflammation is an important initiating process of revascularization 







digest extracellular matrix (ECM) to allow tissue remodeling during subsequent arteriogenesis and 
angiogenesis. The neutrophil is the predominant early-recruited inflammatory leukocyte during 
revascularization, but because it is also recruited during microbial infections, it is not 
discriminating like lymphocytes and will generate reactive oxygen species, produce ECM digesting 
elastases, and secrete inflammatory cytokines regardless of invading pathogens
43
. RvD2 has 
already been shown to be effective in attenuating neutrophil infiltration and reducing their 
cytokine secretion in other inflammatory models
55
. This immunomodulation limits collateral 
inflammation-produced damage and expedites the initiation of resolution, another important 
process of revascularization. During resolution, monocytes and macrophage secrete growth 
factors that stimulate arteriogenesis and angiogenesis and recruit mesenchymal cells to 
regenerate tissue
86
. The decrease in TNF-α and increase in IL-10 suggests that at day 3 post-
occlusion, RvD2-treated animals were tapering inflammation and initiating resolution earlier than 
vehicle-treated animals. Furthermore, Tnfa mRNA also decreased in the hamstring muscles at day 
3, reaffirming our analysis.  
  Other significant changes in cytokines and chemokines were also observed.  We found 
that IL-4 increased in RvD2-treated animals; it is the original stimulator of M2 macrophage 
polarization
81
, and it increases 12/15-lipoxygenase activity in macrophages
156
. M2 macrophage 
polarization is important during revascularization and wound healing, because M2-polarized 
macrophages secrete growth factors instead of inflammatory cytokines (a la M1 inflammatory 
macrophages) to promote revascularization and repair by endothelial cells, vascular smooth 
muscle cells and fibroblasts
157
. We concomitantly measured an increase in the transcription of 
murine M2 marker, Arg1, in the muscle, but no changes in other M2 markers (Mrc1, Retnla, Ym1, 
data not shown) or Alox15 (12/15-LOX gene, data not shown). It is important to emphasize that 







markers are likely time dependent. Additionally, there was also a puzzling lack of RvD2-stimulated 
change in CCL2. CCL2 is a major arteriogenic and angiogenic chemokine stimulated by arterial 
stretching and fluid shear stress to recruit monocytes and macrophages for promoting 
revascularization
158
. This is most likely due to low experiment n and low statistical power as there 
is a promising trend in CCL2 decrease. Furthermore, this can be consistent with a robust RvD2-
arteriogenic response that decreases the need for additional revascularization-promoting 
mediators. This may also explain why GM-CSF, an arteriogenic cytokine, was robustly increased in 
vehicle-treated HLI mice but not in RvD2-treated mice. A randomized, double-blind, placebo 
controlled clinical trial has already proved the promotion of collateral growth by GM-CSF
159
.  
Therefore the robust RvD2-stimulated revascularization response was sufficiently adequate to not 
require GM-CSF. Overall, blood cytokine and chemokine levels may not be entirely indicative of 
gradients at the actual injury site, and allosteric regulation between these soluble mediators can 
produce nonlinear effects that are difficult to reconcile given a single point of analysis. Therefore, 
given the paradoxical enhanced-revascularization dearth of mediator production in our data, we 
needed additional evidence to evaluate if mechanisms of RvD2 actions included stimulation of 
angiogenesis.   
 We evaluated the potential angiogenic mechanism of RvD2 action using an in vivo 
Matrigel plug angiogenesis assay and direct in vitro stimulation of isolated macrophages and 
endothelial cells with RvD2. The Matrigel plug assay is a robust method to interrogate 
angiogenicity: the plug provides an angiogenic environment only; the host mouse mobilizes the 
cells that ultimately vascularize the plug
153
. Because RvD2-treated mice recover acutely, we may 
not have been able to assess accurately RvD2’s angiogenicity in the HLI model. Using the Matrigel 
plug assay, which only measures angiogenesis, allowed us to focus our assessment. Furthermore, 







plug contents is rigorous and objective. That in comparison with the positive control bFGF, RvD2 
did not stimulate any endothelial infiltration into the Matrigel plug, provides strong evidence 
against an angiogenic mode of action of RvD2.  
We also performed additional RvD2-stimulated gene transcription analyses in isolated 
macrophages and endothelial cells. Our results were unremarkable, although there was an 
increase in Mmp14, or membrane type-1 metalloproteinase, which can promote tumor 
angiogenesis in a hypoxia independent manner
160
. No other angiogenic genes were increased 
however. Nevertheless, the in vitro characterization of RvD2 on monocytes and macrophages can 
be improved in the future. Monocytes and macrophages are highly plastic and therefore very 
heterogenous. We only examined the effects of RvD2 on one population of macrophages 
(peritoneal) and with limited forms of stimulation. To characterize the effects of RvD2 on 
monocytes and macrophages more rigorously work with more distinct populations and more 
stimulation methods will need to be performed. 
Endothelial cell proliferation was also tested, via three different assays, and no 
mitogenicity was detected. Although endothelial proliferation is the primary component of 
angiogenesis, it can be stimulated by arteriogenesis, too. The non-mitogenic effect of RvD2, as 
evidenced by the proliferation studies and the Matrigel plug, suggests a more acute process. The 
RvD2-stimulated endothelial migration data supports this acute process. Endothelial migration 
can be stimulated mechanically by fluid shear stress (mechanotaxis), the same force that 
stimulates arteriogenesis
154
.  Shear stress is the component of hemodynamic stress sensed by the 
luminal endothelium and transmitted into the component cells to activate an intricate network of 
migration-mediating GTPases. Specifically, shear stress induces microtubule elongation, which 
then activates Rac to promote actin polymerization and lamellipodia protrusion in the direction of 







required for rear detachment and migration. Additionally, shear stress can increase membrane 
fluidity and initiate signaling cascades from caveolae to activate enzymes such as eNOS. Hence, 
shear stress is a continuous mechanotactic stimulus for endothelial cells and contributes to cell 
migration during arteriogenesis. Our results, demonstrating activation of Rac1 by RvD2, and 
inhibition of RvD2-stimulated migration by Rac1 and eNOS inhibitors, further supports a 
migration-stimulating mechanism. Additionally, in other studies, inhibition of Rac1 or eNOS 
activity by gene knockout impaired revascularization after hind limb ischemia
161-163
. Therefore 
these two proteins and their signaling networks are necessary for revascularization, and because 
RvD2 enhancement of revascularization could result from stimulating these networks. Taken 
together with the in vivo HLI data, we conclude that RvD2 promotes arteriogenesis through the 
stimulation of endothelial migration.  
 Despite all the positive data, we did not provide causative evidence linking endothelial 
migration-stimulation and arteriogenic revascularization by RvD2 during HLI. This can be 
established in future interventional experiments. Inhibiting the RvD2 receptor specifically on 
endothelial cells and reducing revascularization to vehicle-treatment levels, would provide a 
causative link. Unfortunately the RvD2 receptor is currently unknown. Some evidence suggests it 
is a Gαi–linked GPCR, pertussis toxin treatment is sufficient to inhibit HUVEC production of NO
55
. 
In the meantime, another endothelial-specific intervention can provide clues. Endothelial nitric 
oxide synthase is stimulated by fluid shear stress, participates in endothelial migration, and 
expressed specifically in endothelial cells
161
. Repeating the in vivo HLI studies with eNOS knockout 
mice would provide valuable causative insights. Additionally, we can attempt to bypass the more 
arteriogenic phase of revascularization and only begin RvD2 treatment 7 days after HLI surgery. 
This will produce an additional direct test of RvD2 effects on the more angiogenic phase of 







HLI. Patients suffering from critical limb ischemia, and coronary artery disease, are proportionally 
older and possess other comorbidities90. Therefore testing RvD2 efficacy in older and diabetic 
mice would be an important translational investigation.  
 The isolated cellular experiments can be developed further as well. We did not investigate 
the role of VSMC in the HLI model or in in vitro assays. Some RvD2 actions on VSMC have been 
described in another study, but their conclusion was that RvD2 inhibited VSMC proliferation, 
migration, and inflammatory gene transcription
151
. This is paradoxical when compared with the 
endothelial cell (EC) data presented in this study. However, the primary in vivo model in the VSMC 
study was neointimal hyperplasia following vascular injury. This is different from HLI model in this 
present study and therefore differences in results are likely context dependent. Furthermore, 
other vascular mediators, such as NO, can have paradoxical effects as well: NO is critical for 
revascularization, but it also inhibits VSMC proliferation
164
. Therefore additional studies, perhaps 
interrogating the interplay between VSMC and EC, are needed to reconcile these seemingly 
opposing actions.  
 In conclusion, we provide mechanistic evidence supporting the notion that RvD2 
stimulates endothelial migration during arteriogenic revascularization after critical limb ischemia. 
This finding suggests that the endothelium is a primary target of RvD2 during blood perfusion 
recovery. We also provide evidence showing a proliferative and angiogenic role for RvD2. The 
causative link between stimulated migration and enhanced revascularization is missing and 

















 During the course of their lifetime, all organisms have to protect themselves from 
exogenous and endogenous insults that threaten their existence. For animals, the most common 
exogenous insults involve microbial pathogens and traumatic injury leading to physical wounding. 
Endogenous insults often result from autoimmune responses and genetic derangements, but also 
chronic diseases such as respiratory disease, cancer and cardiovascular and cerebrovascular 
disease. Often these diseases are accompanied by tissue ischemia. Collectively, mortality 
associated with tissue injury accounts for 50 % of total mortality in current human societies
117
. 
Like other animals, humans have evolved a highly dynamic, but well-orchestrated inflammatory 
response to neutralize pathogens and heal wounds. An important aspect of this response is tissue 
revascularization. However, the shift to a more sedentary lifestyle and the increase in disease 
comorbidities has outpaced evolutionary adaptations and overwhelmed their capacity to recover 
from ischemic tissue damage. Therefore, therapies to minimize ischemic tissue injury or to 
promote tissue revascularization are urgently needed to diminish the global burden of disease. 
  Recent epidemiological studies of human populations suggest a link between reduction 
of cardiovascular mortality and the consumption of ω-3 polyunsaturated fatty acids, which might 
be related to the beneficial effects on immunity
103
. Although a major function of the immune 
response is to kill invading pathogens, and remove dead tissue, recent immunovascular studies 
show that monocytes and macrophages recruited during the inflammatory response play an 
indispensable role in the revascularization process
165







acids to generate pro-resolving lipid mediators that modulate or resolve the inflammatory 
response55. Taken together this evidence suggests a potential link between cells (monocytes and 
macrophages) that mediate revascularization- and the PUFAs they metabolize. The central 
hypothesis of my work was that pro-resolving lipid mediators produced by monocytes and 
macrophages mediate in part the enhancement of monocyte, macrophage and endothelial cell- 
mediated arteriogenesis and angiogenesis during the revascularization component of ischemic 
wound healing.  
 These investigations began with a direct treatment study to determine if the pro-
resolving lipid mediator, RvD2, can enhance revascularization using a mouse model of hind limb 
ischemia. We induced ischemia in the hind limb of mice by ligating the femoral artery and vein in 
a severe-HLI model and by ligating the saphenous artery and vein in a mild-HLI model. We 
treated mice with RvD2 (or saline) daily, starting one day after HLI surgery, and then we 
monitored the longitudinal recovery of blood perfusion in the severe-HLI model using a laser 
Doppler perfusion imaging system for 14 days. We also quantitated total limb vascular volume 
inferior to the ligation site by Microfil-microCT in severe-HLI mice at 7 days after surgery and 
mild-HLI mice at 3 days. In all three experiments, we measured a significant increase in RvD2-
treated limb perfusion, compared with the level of perfusion in saline-treated limb.  Particularly 
noteworthy is that we began RvD2 treatment 24h after HLI surgery. This protocol was to simulate 
clinical scenario in which treatment is almost always after injury. From these results we conclude 
that treatment with RvD2 enhances revascularization of ischemic wounds.  
 Having established that RvD2 has significant revascularization-enhancing effects in a hind 
limb ischemia model, we next examined the biosynthesis of RvD2 by monocytes involved in 
revascularization. To address this aim we first measured metabolites of 12/15-lipoxygenase, the 







We then measured leukocyte populations in the mouse limbs, at the same revascularization time 
point, and found an increase in the critical revascularization-mediating Ly6Chi CCR2+ inflammatory 
monocytes. Finally, we isolated these inflammatory monocytes from intact mouse spleens and 
determined that they robustly produced RvD2. From this we conclude that revascularization-
mediating inflammatory monocytes are capable of generating the pro-resolving lipid mediator 
RvD2 from the ω-3 fatty acid docosahexaenoic acid.  
 After confirming that monocytes can produce RvD2, we sought to elucidate the 
mechanism by which RvD2 promotes revascularization. For this, we measured RvD2-induced 
changes in ischemic muscle cell populations, mRNA expression, and peripheral blood cytokines 
and chemokines. We found a shift in the inflammation-resolution-revascularization timecourse 
but no major changes in cell populations. We also tested whether RvD2 directly modulated 
arteriogenic genes in isolated macrophages and endothelial cells and found few changes. 
Additionally, we found no evidence for a direct angiogenic effect of RvD2 in a Matrigel plug assay 
as well as endothelial proliferation assays. Nevertheless, we observed that RvD2-promoted 
endothelial migration in a Rac1 and eNOS-dependent manner. Taken together with results from 
other investigators demonstrating RvD2 stimulation of endothelial NO production, we concluded 
that our evidence was consistent with the notion that RvD2 stimulates endothelial migration to 
promote arteriogenesis during revascularization.  
 There are several notable limitations of our study.  Despite the evidence presented, there 
is a lack of data showing that inflammatory monocytes synthesize RvD2 in vivo.   Our data also do 
not establish a causative link between RvD2 stimulation of endothelial migration and enhanced 
arteriogenesis. Although we found also that 12/15-LOX is active and inflammatory monocytes are 
increased during revascularization, and that monocytes can produce RvD2, we did not directly 







approaches in future studies can address this issue by: 1) establishing a detailed timecourse of 
12/15-lipoxygenase activity during the days following HLI in the limb muscle to measure lipid 
mediator production and identify RvD2 biosynthesis; 2) generating a mouse lacking 12/15-LOX 
expression specifically in inflammatory monocytes and demonstrating both a decrease in 
revascularization and ablation of RvD2 generation; and 3)  transplanting inflammatory monocytes 
from 12/15-LOX knockout mice into HLI-operated wild type mice to see whether loss of this 
enzyme prevents  enhancement of revascularization by monocytes. Also, even though we provide 
rigorous evidence supporting an arteriogenic role and migration-enhancing role for RvD2, we do 
not have experimental evidence to causally link these two mechanisms. Establishing this link 
would involve the identification of RvD2 receptor, and selective ablation of this gene in 
endothelial cells, and see whether this would eliminate RvD2-enhanced revascularization. 
Alternatively, or in addition,   RvD2 stimulated signaling networks, such as eNOS and Rac1 could 
be inhibited to determine whether the pro-arteriogenic properties of RvD2 are lost. Addressing 
these two primary limitations of our study will significantly strengthen our hypothesis that that 
RvD2 promotes tissue revascularization after ischemia.  
 The primary conclusion of our study is that RvD2, synthesized by monocytes, increases 
arteriogenic revascularization. Cardiovascular benefits of ω-3 fatty acids have been postulated for 
years, but there have been few mechanistic studies to uncover the signaling pathways that 
mediate the beneficial effects of these fatty acids
107
.  Herein, we present physiologic and 
biochemical evidence of a specific mechanism by which endogenous ω-3 fatty acid metabolites 
can ameliorate a specific cardiovascular injury. These findings address a major unmet clinical 
need. With the cardiovascular portion of the global burden of disease currently at 50% and 







significance. Our identification of RvD2 as a novel revascularization agent is therefore ripe for 
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